NUBURU, Inc. Announces Date for First Quarter 2023 Earnings Release and Conference Call

NUBURU, Inc. Announces Date for First Quarter 2023 Earnings Release and Conference Call

CENTENNIAL, Colo.–(BUSINESS WIRE)–
NUBURU, Inc. (“NUBURU” or the “Company”) (NYSE American: BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced that it will release its financial results for the first quarter ended March 31, 2023, after market close on Thursday, May 11, 2023, followed by a conference call hosted by management at 4:30 p.m. ET.

A live webcast of the conference call will be accessible on NUBURU’s investor relations website at https://ir.nuburu.net. A replay of the webcast will also be available for 90 days at https://ir.nuburu.net. The call can also be accessed from North America at (888) 886-7786, conference ID 93574472.

In addition, NUBURU has posted an updated investor presentation dated May 2, 2023, to its investor relations website at https://ir.nuburu.net.

About NUBURU

Founded in 2015, NUBURU, INC. (NYSE American: BURU) is a developer and manufacturer of industrial blue lasers that leverage fundamental physics and their high-brightness, high-power design to produce faster, higher quality welds and parts than current lasers can provide in laser welding and additive manufacturing of copper, gold, aluminum, and other industrially important metals. NUBURU’s industrial blue lasers produce minimal to defect-free welds that are up to eight times faster than the traditional approaches — all with the flexibility inherent to laser processing. For more information, please visit www.nuburu.net.

NUBURU – Investor Relations Contact

Maria Hocut

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Machinery Machine Tools, Metalworking & Metallurgy Other Manufacturing Manufacturing

MEDIA:

Logo
Logo

Pulmonx Reports First Quarter 2023 Financial Results

REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023.

Recent Highlights

  • Recorded worldwide revenue of $14.5 million in the first quarter of 2023, a 35% increase over the same period last year and an increase of 37% on a constant currency basis
  • Delivered $9.3 million in U.S. revenue in the first quarter of 2023, representing 55% year-over-year growth
  • Realized gross margin of 73% in the first quarter of 2023
  • Added 15 new U.S. treatment centers for Zephyr Valves in the first quarter 2023

“We are pleased with our first quarter performance. As expected, we saw sustained momentum in a more normalized environment, particularly in the U.S.,” said Glen French, President and Chief Executive Officer. “Our experiences over the last two quarters have validated our commercial focus and we are delighted to see strong early traction and receptivity across our account base. We remain confident in our ability to deliver on our year-end goals as we advance our efforts to address the vast unmet need of patients with severe emphysema.”

First Quarter 2023 Financial Results

Total worldwide revenue in the first quarter of 2023 was $14.5 million, a 35% increase from $10.8 million in the first quarter of 2022 and an increase of 37% on a constant currency basis. U.S. revenue was $9.3 million, a 55% increase from the first quarter of 2022. International revenue was $5.2 million, a 9% increase compared to the first quarter of 2022, and a 15% increase on a constant currency basis. The growth in revenue reflects continued commercial momentum and adoption of Zephyr Valve procedures as we are now operating in a more stabilized environment.

Gross profit in the first quarter of 2023 was $10.6 million, compared to $8.1 million for the first quarter of 2022. Gross margin for the first quarter of 2023 was 73%, compared to 75% for the same period in 2022, reflecting slightly lowered capacity utilization.

Operating expenses in the first quarter of 2023 were $27.0 million, compared to $23.8 million for the first quarter of 2022, representing an increase of 13%. The increase in operating expenses was primarily attributable to an increase in clinical and development investments related to our AeriSeal program, an increase in sales and marketing costs, and an increase in legal and stock-based compensation expenses.  

Net loss in the first quarter of 2023 was $15.9 million, or $0.42 per share, compared to a net loss of $15.8 million, or $0.43 per share, for the same period in 2022.

Adjusted EBITDA loss in the first quarter of 2023 was $11.2 million compared to $11.8 million for the same period in 2022.

Cash, cash equivalents, and marketable securities totaled $155.5 million as of March 31, 2023 and include the $20 million drawdown on our existing term loan which occurred in February of 2023.

2023 Financial Outlook

Pulmonx continues to expect revenue for the full year 2023 to be in the range of $63 million to $65 million.

The Company also continues to expect gross margin for the full year 2023 to fall within the range of 73% to 74%.

Pulmonx continues to expect total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based compensation.

Webcast and Conference Call Details

Pulmonx will host a conference call today, May 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its first quarter financial results. A live webcast of the conference call will be available on the Investor Relations section of the Company’s website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures

To supplement Pulmonx’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, Pulmonx provides certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx’s business.

Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management’s financial and operational decision-making, including evaluation of Pulmonx’s historical operating results.

The Company defines Adjusted EBITDA as earnings before interest income or expense, taxes, depreciation and amortization and stock-based compensation and may also exclude certain non-recurring, irregular or one-time items not reflective of our ongoing core business operations. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. Further, management uses adjusted EBITDA for strategic and annual operating planning. We believe these non-GAAP financial measures are useful as a supplement in evaluating our ongoing operational performance and enhancing an overall understanding of our past financial performance.

Reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is set forth in the tables below.

The non-GAAP financial measures used by Pulmonx should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the company’s reported results of operations, management strongly encourages investors to review, when they become available, the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company’s definition of non-GAAP measures may differ from similarly titled measures used by others.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our commercial strategy to boost workflow efficiencies across our account base, our expectations regarding account activity and productivity, information concerning the impact of the COVID-19 pandemic on us and our operations, a recovery and growth in the number of procedures performed, the size and penetration of the Japanese market for our products, our plans for commercial launch in Japan in fiscal year 2023 and the success thereof, advancement of our AeriSeal clinical development program toward commencement of our U.S. clinical trial, the timing of trial enrollment and data results from the CONVERT trial and commencement of our U.S. Investigational Device Exemption (“IDE”) trial, and our possible or assumed future results of operations, including long-term outlook, descriptions of our revenues, total operating expenses, gross margin, profitability, guidance for full year 2023, commercial momentum, physician engagement and awareness of the benefits of the Zephyr Valve, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), including the Annual Report on Form 10-K filed with the SEC on March 1, 2023, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Investor Contact

Brian Johnston
Gilmartin Group
[email protected]

Pulmonx Corporation

Consolidated Statements of Operations

(in thousands, except share and per share data)

(Unaudited)
       
       
  Three Months Ended March 31,
    2023       2022  
Revenue $ 14,535     $ 10,785  
Cost of goods sold   3,946       2,674  
Gross profit   10,589       8,111  
Operating expenses      
Research and development   4,253       3,534  
Selling, general and administrative   22,736       20,245  
Total operating expenses   26,989       23,779  
Loss from operations   (16,400 )     (15,668 )
Interest income   1,127       105  
Interest expense   (571 )     (198 )
Other income (expense), net   108        
Net loss before tax   (15,736 )     (15,761 )
Income tax expense   124       67  
Net loss $ (15,860 )   $ (15,828 )
Net loss per share attributable to common stockholders, basic and diluted $ (0.42 )   $ (0.43 )
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted   37,572,382       36,805,366  
Pulmonx Corporation

Condensed Consolidated Balance Sheets

(in thousands)

(Unaudited)
       
  March 31, 2023   December 31, 2022
Assets      
Current assets      
Cash and cash equivalents $ 110,407     $ 101,736  
Restricted cash   231       231  
Short-term marketable securities   42,429       39,402  
Accounts receivable, net   8,171       8,677  
Inventory   15,588       14,564  
Prepaid expenses and other current assets   4,472       4,343  
Total current assets   181,298       168,953  
Long-term marketable securities   2,637       5,924  
Long-term inventory   4,774       5,283  
Property and equipment, net   4,490       4,694  
Goodwill   2,333       2,333  
Intangible assets, net   123       154  
Right of use assets   5,152       5,806  
Other long-term assets   465       529  
Total assets $ 201,272     $ 193,676  
Liabilities and Stockholders’ Equity      
Current liabilities      
Accounts payable $ 2,890     $ 1,758  
Accrued liabilities   10,632       13,276  
Income taxes payable   60       19  
Deferred revenue   107       120  
Short-term debt   91       90  
Current lease liabilities   3,299       3,229  
Total current liabilities   17,079       18,492  
Deferred tax liability   71       94  
Long-term lease liabilities   3,015       3,849  
Long-term debt   37,173       17,234  
Total liabilities   57,338       39,669  
Stockholders’ equity      
Common stock   38       38  
Additional paid-in capital   508,254       502,712  
Accumulated other comprehensive income   1,820       1,575  
Accumulated deficit   (366,178 )     (350,318 )
Total stockholders’ equity   143,934       154,007  
Total liabilities and stockholders’ equity $ 201,272     $ 193,676  
Pulmonx Corporation

Reconciliation of Reported Revenue % Change to Constant Currency Revenue % Change

(in thousands)

(Unaudited)
               
  Three months ended March 31,            
    2023       2022     % Change   FX Impact %   Constant Currency % Change
United States $ 9,337     $ 6,013       55.3 %     %     55.3 %
International   5,198       4,772       8.9 %     (5.7 )%     14.6 %
Total $ 14,535     $ 10,785       34.8 %     (2.5 )%     37.3 %
Pulmonx Corporation

Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA

(in thousands)

(Unaudited)
   
  Three months ended March 31,
    2023       2022  
GAAP Net loss $ (15,860 )   $ (15,828 )
Depreciation and amortization   437       368  
Stock-based compensation   4,638       3,513  
Interest (income)/expense, net   (556 )     93  
Provision for income taxes   124       67  
Adjusted EBITDA $ (11,217 )   $ (11,787 )



Pathfinder Bancorp, Inc. Announces First Quarter 2023 Net Income of $2.6 Million

Results Highlight Stable Liquidity, Strong Asset Quality, Expanding Revenue and Expanding Reach

OSWEGO, N.Y., May 02, 2023 (GLOBE NEWSWIRE) — Pathfinder Bancorp, Inc. (“Company”) (NASDAQ: PBHC), the holding company for Pathfinder Bank (“Bank”), announced first quarter 2023 net income available to common shareholders of $2.6 million, or $0.43 per basic and diluted share. The first quarter results in 2023 were slightly lower than the $3.0 million, or $0.49 per basic and diluted share earned in the first quarter of 2022. The Company’s total revenue, which is comprised of net interest income, before provision for credit losses, and total noninterest income, for the first quarter of 2023 was $11.6 million, increasing by $490,000, or 4.4%, compared to the same quarter in 2022.


First Quarter 2023 Performance Highlights

  • Notable growth in total interest-earning assets, which increased to $1.32 billion for the quarter ended on March 31, 2023, up 5.9% from $1.25 billion for the quarter ended March 31, 2022 and up 0.8% from $1.31 billion for the quarter ended December 31, 2022.
  • Total loans increased to $910.2 million at the end of the first quarter of 2023, reflecting a $54.6 million, or 6.4%, increase from March 31, 2022, and a $12.4 million, or 1.4%, increase from year-end 2022.
  • Total deposits reached $1.14 billion on March 31, 2023, a 2.7% increase from March 31, 2022, and a 1.7% increase from December 31, 2022. The growth in deposits in the first quarter of 2023 was an indication of continued stability within the Bank’s deposit base.
  • Net interest income, before the provision for credit losses, increased by 5.3% to $10.0 million in the first quarter of 2023 compared to the prior year period, as the net interest margin contracted by only four basis points to 3.02%, despite significant upward pressure on the Bank’s cost of funds.
  • Tangible book value per common share rose by 1.7% to $17.75, up from $17.45 one year prior, including the effects of a $0.36 per share one-time adjustment recorded in the quarter related to the Company’s transition to the Current Expected Credit Loss methodology for calculating credit loss reserves on financial assets.

James A. Dowd, President, and Chief Executive Officer, expressed his confidence in the Bank’s long-term growth prospects, citing its commitment to providing exceptional service to customers in Central New York as a key factor behind the Bank’s sustainable profitability, solid liquidity, and customer loyalty. Mr. Dowd highlighted the Bank’s ongoing efforts to improve its margins, expressing optimism about future growth prospects, and reaffirming the Bank’s commitment to serving customers with excellence over the long term.

“As many of our peer institutions have reported, Pathfinder faced a number of challenges in the first quarter of 2023, primarily related to significant upward pressures on the Bank’s cost of funds,” said Mr. Dowd. “However, as we are coming off of record earnings in 2022, we believe that Pathfinder is well-positioned for continued measured and profitable growth.”

“Despite the pressures that almost all depository institutions are experiencing related to their cost of funds, we grew total revenue, excluding the provision for credit losses, to $11.6 million, up 4.4% from the same period in the prior year. During the first quarter of 2023, the annualized return on average assets was 0.75% and the annualized return on average equity was 9.2%. While these profitability metrics declined from the previous year, largely due to increases in our provisioning for credit losses, we continue to believe that we will achieve gains in these metrics throughout the remainder of 2023.”

“As we have expected, noninterest expenses also increased from the prior year period as we responded to inflationary and wage pressures within our markets. We will maintain our focus on effective expense management, while ensuring that we are continuing to make prudent investments to unlock our longer-term growth potential. Among those investments is our newest branch location in the City of Syracuse, which we have operated since the middle of November 2022. The new full-service branch in Syracuse’s Southwest Corridor area has most certainly brought a broad range of community banking services to an area that we believe was significantly underserved. In addition, this new branch has provided an additional point of convenient service access for our growing customer base in downtown Syracuse, where we have already established a successful presence.”

“Looking ahead, we are excited by the growth opportunities we see for both the Company and the regions that we serve. In October of 2022, Micron Technology, Inc. (NYSE: MU) announced its plans to spend up to $100 billion building a mega-complex of computer chip fabrication facilities in Syracuse’s northern suburbs, where we already have a strong branch presence, in what would be the largest, most significant single private investment in New York history. This announcement has brought renewed optimism and excitement for the future of our region. It is expected that Micron’s projects, and the follow-on growth and investment associated with those projects, will significantly transform the Central New York economy and improve the quality of life in its communities for years to come.”

“We believe that our brand recognition and physical presence in Central New York positions us extremely well to take advantage of the unprecedented economic growth opportunity in our local market. A project of this magnitude and its potential economic impact will create opportunities for existing businesses to benefit from significant employment expansion and development while attracting new businesses to the region and adding thousands of new employees to our area, thereby creating additional needs for local services. The addition of more quality employment opportunities in Central New York will benefit all companies in the region as the area becomes more attractive for talented individuals, creating larger candidate pools of local talent. Housing stock will be needed for this influx of talent, creating opportunities for homebuilders, remodelers, and related subcontractors, suppliers, and manufacturers. The future economic outlook for the Central New York region has never been brighter, and we are well-positioned to be a part of this growth story.”

“Despite increases in the provision for credit losses recorded in the first quarter of 2023, as compared to the same quarter in the previous year, the Bank’s credit quality continues to be well managed with our $910.2 million loan portfolio producing a ratio of nonperforming loans to total loans of 2.1% at March 31, 2023. Our ratio of allowance for credit losses to nonperforming loans stood at 98.79% at quarter end. The provision for credit losses increased in the quarter, again in comparison to the same quarter last year, as the Bank continued to evaluate all risks associated with the loan portfolio and identify the need for certain credit downgrades on a small number of large loan relationships.”

“While we do anticipate that loan demand will slow from the robust levels experienced in the months following the COVID-19 pandemic, we will continue to maintain our prudent and consistent underwriting standards as we move forward. In the very near-term, the Bank remains well-positioned for a rising rate environment, having successfully navigated rapid interest rate increases over the past year, and we have continued to improve the Bank’s funding mix, although interest margins will continue to be under pressure as the deposit gathering environment remains extremely competitive. We continue to believe that our strong financial performance, dedicated and highly capable team and healthy capital position leaves us well-positioned for the remainder of 2023.”


Income Statement for the Quarter Ended March 31, 2023

First quarter 2023 net income was $2.6 million, a decrease of $351,000, or 11.9% from $3.0 million in the first quarter of the previous year. Net interest income, before provision for credit losses, increased by $501,000, or 5.3%, in the first quarter of 2023 to $10.0 million, compared to $9.5 million for the same quarter in 2022. The increase in net interest income between comparable quarters was primarily due to the $4.1 million, or 37.0%, increase in interest and dividend income in the first quarter of 2023. Interest and dividend income increased to $15.0 million, compared to $11.0 million in the same quarter in 2022. These improvements in interest and dividend income were partially offset by an increase in interest expense for the first quarter of 2023 of $3.6 million, or 235.0%, to $5.1 million, from $1.5 million for the prior year quarter.

The quarter-over-quarter improvement in net interest income before provision for credit losses, discussed above, was more than offset by a $590,000 increase in the provision for credit losses recorded in the first quarter of 2023, see Asset Quality for additional information. The Bank reported a provision for credit losses of $692,000 for the first quarter of 2023, compared to a $102,000 provision for loan losses for the first quarter of 2022. Therefore, net interest income, after provision for credit losses, decreased by $89,000, or 1.0%, in the first quarter of 2023 to $9.3 million, compared to $9.4 million for the same quarter in 2022.

During the first quarter of 2023, the Company’s noninterest income was essentially unchanged at $1.6 million, with a recorded decrease of $11,000, or 0.7%, compared to the same period in 2022. Total revenues after provision for credit losses therefore decreased $100,000, or 0.1%, to $10.9 million from $11.0 million in the same quarter of the previous year. Noninterest expense increased in the first quarter of 2023, as compared to the same quarter in the previous year, by $272,000, or 3.8%. 

In the first quarter of 2023, the Company’s total revenue was $11.6 million, an increase of 4.4%, from the year-ago period. As noted above, profitability declined modestly in the first quarter of 2023, as compared to the same quarter in 2022, resulting in decreases in key earnings ratios, including return on average assets of 0.75% and return on equity of 9.20%.


Components of Net Interest Income

In the first quarter of 2023, net interest income, before provision for credit losses, for the Company increased by $501,000, or 5.3%, compared to the same quarter in 2022, reaching a total of $10.0 million. Interest and dividend income in the first quarter of 2023 was $15.0 million, compared to $11.0 million in the same quarter in 2022. The increase in interest and dividend income between comparable quarters was the result of a $2.0 million increase in loan interest income and a $2.0 million increase in interest income derived from investments in taxable and tax-exempt investment securities. The increase in interest and dividend income was also the result of a 63 basis point increase in the average loan yield, accompanied by a $53.8 million increase in the average outstanding balance of loans and a 170 basis point increase in the average yield on investment securities, accompanied by a $42.9 million increase in the average outstanding balance of investment securities. Partially offsetting those increases was an increase in total interest expense for the first quarter of 2023 to $5.1 million, an increase of $3.6 million, or 235.0%, from $1.5 million for the prior year quarter. Interest expense increased due to a 127 basis point increase in average rates paid on interest-bearing liabilities, accompanied by an increase in the average outstanding balance of those liabilities of $85.2 million. The increase in the quarterly interest expense was primarily a result of the increase in cost of deposits resulting from the rapidly rising interest rate environment. The deposit mix included a $77.1 million increase in average time deposit balances combined with a 166 basis point increase in the average interest rate paid on those deposits.

The resultant net interest margin for the first quarter of 2023 was 3.02%, a four basis point decrease compared to a net interest margin of 3.06% in the first quarter of 2022. Over the past year, the Company’s management has been able to effectively manage net interest margin by active management of the Bank’s assets and liabilities in the current challenging interest rate environment.


Provision for Credit Losses

Management believes that the Bank has taken a prudent and conservative approach towards risk management by reporting a provision for credit losses of $692,000 for the first quarter of 2023, in reflection of the prevailing economic environment. This is a significant increase compared to the provision for loan losses of $102,000 reported for the same period in 2022. The Bank has been carefully monitoring the credit-sensitive portfolios and will continue to apply its proven conservative loan classification and reserve building methodologies to analyze these portfolios. The Bank remains committed to evaluating the situation in the coming quarters, ensuring the sustained stability and resilience of its financial position, see Asset Quality for additional information.

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments—Credit Losses(Topic 326): Measurement of Credit Losses on Financial Instruments, requiring financial institutions, such as the Bank, to adopt the Current Expected Credit Loss (“CECL”) methodology according to a specified implementation timeline. In order to meet this requirement, the Bank adopted the CECL methodology for calculating its Allowance for Credit Losses (“ACL”) on January 1, 2023. The amended guidance replaces the previously-required Allowance for Loan and Lease Losses (“ALLL”) calculated under what was known as the Incurred Loss Model. The ACL represents a valuation account that is deducted from the amortized cost basis of includable financial assets to present their net carrying value at the amount expected to be collected over the entire life of those assets. The income statement now reflects the measurement of credit losses for newly recognized financial assets as well as expected increases, or decreases, of expected credit losses that have taken place during the reporting period. When determining the ACL, expected credit losses over the expected term of the financial asset will be estimated considering relevant information about past events, current conditions, and reasonable and supportable forecasts that affect the future collectability of the reported amount. In addition, the amended guidance requires credit losses relating to assets such as held-to-maturity debt securities and open contractual funding commitments to be recorded through the ACL. Because the CECL methodology requires that reserves be established within the ACL for a broad range of financial assets, including all loans, through the entirety of their expected lives and also considers new items, such as open funding commitments, the initial ACL upon adoption would, in most cases, be expected to be greater than the ALLL that it replaced.

The transition adjustment that was recognized upon the adoption of CECL on January 1, 2023, was accounted for as a one-time increase in the ACL with a corresponding one-time adjustment to retained earnings, adjusted for income tax effects. This transition adjustment did not impact earnings or earnings per share at adoption. The required CECL transition adjustment resulted in an increase of $2.9 million in the ACL. Retained earnings at March 31, 2023 therefore reflects the effects of the one-time transition adjustment of $2.1 million, recorded on January 1, 2023, after income tax effects. This one-time adjustment to retained earnings resulted in a reduction of approximately $0.36 per share in the Company’s tangible book value, after tax effects as of the adoption date.


Noninterest Income

During the first quarter of 2023, the Company’s noninterest income was essentially unchanged at $1.6 million, with a recorded decrease of $11,000, or 0.7%, compared to the same period in 2022. Recurring noninterest income that excludes certain items that can cause volatility in noninterest income, such as unrealized gains or losses on equity securities, and nonrecurring gains on sales of loans, investment securities, foreclosed real estate, premises and equipment, was also essentially unchanged in the first quarter of 2023, as compared to the first quarter of the previous year.

The following table details the components of noninterest income for the three months ended March 31, 2023, and 2022:

Unaudited For the three months ended  
(Dollars in thousands) March 31, 2023     March 31, 2022     Change  
Service charges on deposit accounts $ 267     $ 259     $ 8       3.1 %
Earnings and gain on bank owned life insurance   158       162       (4 )     -2.5 %
Loan servicing fees   72       117       (45 )     -38.5 %
Debit card interchange fees   321       228       93       40.8 %
Insurance agency revenue   420       299       121       40.5 %
Other charges, commissions and fees   256       413       (157 )     -38.0 %
Noninterest income before gains   1,494       1,478       16       1.1 %
Net gains on sales of securities, fixed assets, loans and foreclosed real estate   98       57       41       71.9 %
Gains on marketable equity securities         68       (68 )     -100.0 %
Total noninterest income $ 1,592     $ 1,603     $ (11 )     -0.7 %
                               


Noninterest Expense

Total noninterest expense for the first quarter of 2023 was $7.5 million, an increase of $272,000, or 3.8%, from the same three-month period in 2022. Noninterest expense for the first quarter of 2023, in comparison to the same quarter in the previous year, was driven by increases in salaries and benefits expense of $134,000, or 3.3%, and aggregate increases in all other expense categories of $138,000, or 4.3%. The $134,000 increase in salaries and benefits expense for the three months ended March 31, 2023, as compared to the same three month period in 2022, was primarily due to increases in individual staff salaries and certain commissions paid related to insurance and investment services activities. Staffing increases in the Bank’s branch system were made as a result of the opening of the Bank’s eleventh branch in November 2022. During the first quarter of 2023, the Company increased its salary structure where it was deemed appropriate in order to effectively respond to inflationary and competitive pressures within our marketplace to recruit and retain talent. Further increases within the Company’s personnel expenses are anticipated throughout the remainder of 2023 as certain position vacancies are filled and further compensation adjustments, in a limited number of areas are realized. The Bank’s decision to invest in its workforce demonstrates its dedication to building a strong, skilled, and satisfied team of professionals, which is viewed by management as vital for maintaining a competitive edge in the ever-evolving banking sector.

The following table details the components of noninterest expense for the three months ended March 31, 2023, and 2022:

Unaudited For the three months ended  
(Dollars in thousands) March 31, 2023     March 31, 2022     Change  
Salaries and employee benefits $ 4,183     $ 4,049     $ 134       3.3 %
Building and occupancy   852       826       26       3.1 %
Data processing   553       550       3       0.5 %
Professional and other services   536       393       143       36.4 %
Advertising   206       187       19       10.2 %
FDIC assessments   219       222       (3 )     -1.4 %
Audits and exams   159       141       18       12.8 %
Insurance agency expense   261       204       57       27.9 %
Community service activities   30       62       (32 )     -51.6 %
Foreclosed real estate expenses   14       13       1       7.7 %
Other expenses   511       605       (94 )     -15.5 %
Total noninterest expenses $ 7,524     $ 7,252     $ 272       3.8 %
                               


Balance Sheet on March 31, 2023

On March 31, 2023, the Company’s total assets were $1.4 billion, reflecting growth of $3.7 million, or 0.3%, when compared to December 31, 2022. This increase was driven by an increase in gross loan balances of $12.4 million, or 1.4%, from $897.8 million on December 31, 2022 to $910.2 million at March 31, 2023, partially offset by a decline in all other assets of $8.7 million. During the quarter, management placed significant emphasis on building both balance sheet and contingent liquidity, electing to focus on deposit gathering and improvements in the Bank’s asset and liability mixes.

During the first quarter of 2023, the Bank’s total deposits increased by $18.8 million, or 1.7%, reaching $1.14 billion on March 31, 2023. The Bank experienced growth in interest-bearing deposits, which rose by $20.9 million, or 2.2%, reaching $962.6 million at March 31, 2023, while noninterest-bearing deposits decreased by $2.1 million, or 1.1%, to $181.6 million at March 31, 2023. This growth in interest-bearing deposits continues to indicate stable liquidity for the Bank, providing a reliable source of funds to support lending activities and other operations. 

Shareholders’ equity increased modestly by $703,000, or 0.6%, from $111.0 million at December 31, 2022, to $111.7 million on March 31, 2023. This increase was primarily due to the Company’s recorded net income of $2.6 million in the quarter, partially reduced by the dividend declaration to shareholders of $551,000. As noted above, on January 1, 2023, the Company adopted the CECL methodology for computing its ACL and related provision for credit losses. This adoption resulted in the recognition of a one-time transitional adjustment that reduced the Company’s retained earnings by $2.1 million, net of tax, on that date. In total therefore, including the adjustment, retained earnings decreased $86,000 in the quarter ended March 31, 2023. The effects of this net reduction in retained earnings were offset by a decrease in accumulated other comprehensive loss of $638,000 and an increase in all other components of shareholders’ equity of $151,000. 

The following table details the changes in shareholders’ equity that occurred in the quarter ended March 31, 2023:

(In thousands, except share and per share data)   Common Stock   Non-Voting Common Stock   Additional Paid in Capital   Retained Earnings   Accumulated Other Comprehensive Loss   Unearned ESOP   Non-controlling Interest   Total
Balance, January 1, 2023   $ 47     $ 14     $ 52,101     $ 71,322     $ (12,172 )   $ (315 )   $ 585     $ 111,582  
Net income                       2,599                   76       2,675  
Other comprehensive income, net of tax                             638                   638  
ESOP shares earned (6,111 shares)                 70                   45             115  
Stock based compensation                 36                               36  
Common stock dividends declared ($0.09 per share)                       (416 )                       (416 )
Non-Voting common stock dividends declared ($0.09 per share)                       (124 )                       (124 )
Warrant dividends declared ($0.09 per share)                       (11 )                       (11 )
Adoption of ASU 2016-13 Current Expected Credit Losses                       (2,134 )                       (2,134 )
Balance, March 31, 2023   $ 47     $ 14     $ 52,207     $ 71,236     $ (11,534 )   $ (270 )   $ 661     $ 112,361  
                                                                 


Asset Quality

During the first quarter of 2023, certain Bank asset quality metrics declined primarily due to the downgrading of two significant loan relationships. The balance of nonaccrual loans related to these two relationships increased to 24 loans, with an aggregate outstanding balance of $13.0 million at March 31, 2023, as compared to five loans with an aggregate outstanding balance of $1.7 million at December 31, 2022. Primarily as a consequence of the increase in nonperforming loans related to these two relationships, nonperforming loans, as a percentage of total loans, increased to 2.1% on March 31, 2023, in comparison to 1.0% on December 31, 2022, and 0.9% on March 31, 2022. 

The allowance for credit losses to non-performing loans at March 31, 2023 was 98.79%, compared with 163.8% at March 31, 2022, which reflects the impact of the increases in nonperforming loans, discussed above. Management is closely monitoring all nonaccrual loans and has incorporated its current estimate of the ultimate collectability of these loans into the reported allowance for credit losses at March 31, 2023.

The following table summarizes nonaccrual loans by category and status at March 31, 2023:

(In thousands)                          
Loan Type Collateral Type Number of Loans     Loan Balance     Average Loan Balance     Weighted LTV at Origination/ Modification   Status
Secured residential mortgage:                        
  Real Estate   15     $ 1,372     $ 91       77 %   Individual loans are under active resolution management by the Bank.
                           
Secured commercial real estate:                        
  Private Museum   1       1,380       1,380       79 %   The borrower is expected to receive specific government grant funding this year and be finalized by the end of 2023. This will allow for a reduction of the outstanding loan balance upon their finalization.
  Office Space   1       1,682       1,682       78 %   The loan is secured by a first mortgage with strong tenancy and a long-term lease. The borrower is seeking outside financing and the Bank is in regular communication with the borrower.
  Manufacturing   1       1,341       1,341       54 %   The loan is secured by a first mortgage with strong tenancy and a long-term lease. The borrower is seeking outside financing and the Bank is in regular communication with the borrower.
  All other   10       2,543       254       118 %   Individual loans are under active resolution management by the Bank.
                           
Commercial lines of credit:     8       2,693       337     (1 )   Individual lines are under active resolution management by the Bank.
                           
Commercial and industrial loans:     15       6,062       404     (1 )   Individual loans are under active resolution management by the Bank.
                           
Consumer loans:     14       2,029       145     (1 )   Individual loans are under active resolution management by the Bank.
      65     $ 19,102                
                               

(1) These particular loans were originated as unsecured or with minimal collateral.


Liquidity

Balance sheet liquidity, as well as the availability of sufficient contingent funding sources for banks are currently of both emerging and significant concern to depositors, industry regulators and investors. Management believes that the Bank has an appropriate level of balance sheet liquidity in the form of cash on hand and from the expected cash flows generated by its loan and investment securities to meet all of its foreseeable funding obligations in the future. The Bank’s nonbrokered deposit balances increased $21.9 million, or 2.5%, from $876.8 million at December 31, 2022 to $898.7 million at March 31, 2023 and the Bank maintains robust marketing and customer acquisition programs specifically directed towards deposit gathering. In addition, the Bank has a long-established relationship with the Federal Home Loan Bank of New York (“FHLB-NY”) that allows the Bank access to the wide variety of advance facilities that the FHLB-NY offers. The Bank had $51.7 million in immediately-available additional funding capacity with the FHLB-NY at March 31, 2023. In addition, other currently-available and unused lines of credit, including those that could be supplied through the Federal Reserve’s Discount Window, total $25.4 million. The Bank can also readily qualify itself for the Federal Reserve’s new Bank Term Funding Program (“BTFP”) announced in March 2023. This program allows depository institutions to pledge specific types of investment securities regardless of their designation as either available-for-sale or held-to-maturity, at par, as collateral for one-year callable term advances offered at market rates. The Bank may elect to access this funding source prior to its currently-scheduled expiration date in March 2024, or any of its other available funding sources, as detailed above, if management considers these actions to be advantageous in managing the Bank’s liquidity profile in the future.

The Bank’s management monitors liquidity on a continuous basis through a broad range of internal programs and considers effective liquidity management to be one of its primary objectives. At March 31, 2023 the Bank had deposits of $1.1 billion, of which $382.7 million were nominally uninsured, as they were above the insurance limits established by the Federal Deposit Insurance Corporation (“FDIC”) on that date. Of the $382.7 million in nominally uninsured deposits at March 31, 2023, $72.6 million were insured through a long-standing reciprocal deposit program managed by a third-party entity. In addition, $121.0 million in municipal deposits are fully protected against principal loss by a collateral program whereby the Bank places high-quality securities with an independent custodian as collateral. Therefore, the Bank had $189.1 million in deposits, representing 16.5% of all deposits, that were considered to be uninsured at March 31, 2023. 


Cash Dividend Declared

On April 4, 2023, the Company announced the declaration of its cash dividend for the fiscal quarter ended March 31, 2023. The Board of Directors declared a cash dividend of $0.09 per share on the Company’s voting common and non-voting common stock, and a cash dividend of $0.09 per notional share for the Company’s issued warrant. The dividend will be payable to all shareholders of record on April 24, 2023, and will be paid on May 19, 2023. The implied dividend yield, based on the closing price of the Company’s common stock on March 31, 2023 of $17.27, is 2.1%. The quarterly cash dividend of $0.09 represents a dividend payout ratio of 21.2%.


About Pathfinder Bancorp, Inc.

Pathfinder Bank is a New York State chartered commercial bank headquartered in Oswego, whose deposits are insured by the Federal Deposit Insurance Corporation. The Bank is a wholly owned subsidiary of Pathfinder Bancorp, Inc., (NASDAQ SmallCap Market; symbol: PBHC). The Bank has eleven full-service offices located in its market areas consisting of Oswego and Onondaga County and one limited purpose office in Oneida County. Through its subsidiary, Pathfinder Risk Management Company, Inc., the Bank owns a 51% interest in the FitzGibbons Agency, LLC. At March 31, 2023, there were 4,651,829 shares of voting common stock issued and outstanding, as well as 1,380,283 shares of non-voting common stock issued and outstanding. The Company’s common stock trades on the NASDAQ market under the symbol “PBHC.” At March 31, 2023, the Company and subsidiaries had total consolidated assets of $1.40 billion, total deposits of $1.14 billion and shareholders’ equity of $111.7 million.


Forward-Looking Statement

Certain statements contained herein are “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are generally identified by use of the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “project” or similar expressions, or future or conditional verbs, such as “will,” “would,” “should,” “could,” or “may.” These forward-looking statements are based on current beliefs and expectations of the Company’s and the Bank’s management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond the Company’s and the Bank’s control. In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Actual results may differ materially from those set forth in the forward-looking statements as a result of numerous factors. Factors that could cause such differences to exist include, but are not limited to: risks related to the real estate and economic environment, particularly in the market areas in which the Company and the Bank operate; fiscal and monetary policies of the U.S. Government; inflation; changes in government regulations affecting financial institutions, including regulatory compliance costs and capital requirements; fluctuations in the adequacy of the allowance for credit losses; decreases in deposit levels necessitating increased borrowing to fund loans and investments; the effects of the COVID-19 pandemic; operational risks including, but not limited to, cybersecurity, fraud and natural disasters; the risk that the Company may not be successful in the implementation of its business strategy; changes in prevailing interest rates; credit risk management; asset-liability management; and other risks described in the Company’s filings with the Securities and Exchange Commission, which are available at the SEC’s website, www.sec.gov.

This release contains non-GAAP financial measures. For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a registrant’s historical or future financial performance, financial position, or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the statement of income, balance sheet, or statement of cash flows (or equivalent statements) of the registrant; or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented. In this regard, GAAP refers to generally accepted accounting principles in the United States. Pursuant to the requirements of Regulation G, the Company has provided reconciliations within the release of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

PATHFINDER BANCORP, INC.

FINANCIAL HIGHLIGHTS

(Dollars and shares in thousands except per share amounts)

  For the three months
 
  ended March 31,
 
  (Unaudited)
 
  2023
 
  2022
 
Condensed Income Statement          
Interest and dividend income $ 15,043     $ 10,982  
Interest expense   5,075       1,515  
Net interest income   9,968       9,467  
Provision for credit losses   692       102  
    9,276       9,365  
Noninterest income excluding net gains on sales of securities, fixed assets, loans and foreclosed real estate   1,494       1,478  
Net gains on sales of securities, fixed assets, loans and foreclosed real estate   98       57  
Gains on marketable equity securities         68  
Noninterest expense   7,524       7,252  
Income before income taxes   3,344       3,716  
Provision for income taxes   669       721  
           
Net income attributable to noncontrolling interest and Pathfinder Bancorp, Inc. $ 2,675     $ 2,995  
Net income attributable to noncontrolling interest   76       45  
Net income attributable to Pathfinder Bancorp Inc. $ 2,599     $ 2,950  
               

  As of and For the Periods Ended
 
  March 31,
 
  December 31,
 
  March 31,
 
  2023
 
  2022
 
  2022
 
  (Unaudited)  
Selected Balance Sheet Data                
Assets $ 1,403,717     $ 1,399,921     $ 1,328,415  
Earning assets   1,323,300       1,313,069       1,249,941  
Total loans   910,154       897,754       855,601  
Deposits   1,144,262       1,125,430       1,114,077  
Borrowed funds   99,205       115,997       62,521  
Allowance for credit losses   18,871       15,319       13,017  
Subordinated debt   29,777       29,733       29,604  
Pathfinder Bancorp, Inc. Shareholders’ equity   111,700       110,997       109,055  
                 
Asset Quality Ratios                
Net loan charge-offs (annualized) to average loans   0.01 %     0.04 %     0.01 %
Allowance for credit losses to period end loans   2.07 %     1.71 %     1.52 %
Allowance for credit losses to nonperforming loans   98.79 %     169.93 %     163.78 %
Nonperforming loans to period end loans   2.10 %     1.00 %     0.93 %
Nonperforming assets to total assets   1.38 %     0.66 %     0.60 %
                       

The above information is preliminary and based on the Company’s data available at the time of presentation.

PATHFINDER BANCORP, INC.

FINANCIAL HIGHLIGHTS

(Dollars and shares in thousands except per share amounts)

  For the three months
 
  ended March 31,
 
  (Unaudited)
 
  2023
 
  2022
 
Key Earnings Ratios          
Return on average assets   0.75 %     0.90 %
Return on average common equity   9.20 %     10.63 %
Return on average equity   9.20 %     10.63 %
Net interest margin   3.02 %     3.06 %
           
Share, Per Share and Ratio Data          
Basic and diluted weighted average shares outstanding -Voting   4,609       4,536  
Basic and diluted earnings per share – Voting $ 0.43     $ 0.49  
Basic and diluted weighted average shares outstanding – Series A Non-Voting   1,380       1,380  
Basic and diluted earnings per share – Series A Non-Voting $ 0.43     $ 0.49  
Cash dividends per share $ 0.09     $ 0.09  
Book value per common share at March 31, 2023 and 2022 $ 18.52     $ 18.23  
Tangible book value per common share at March 31, 2023 and 2022 $ 17.75     $ 17.45  
Tangible common equity to tangible assets at March 31, 2023 and 2022   7.65 %     7.89 %
Tangible common equity to tangible assets at March 31, 2023 and 2022, adjusted   7.65 %     7.97 %
               

Throughout the accompanying document, certain financial metrics and ratios are presented that are not defined under generally accepted accounting principles (GAAP).  Reconciliations of the non-GAAP financial metrics and ratios, presented elsewhere within this document, are presented below:

  For the three months
 
  ended March 31,
 
  (Unaudited)
 
Non-GAAP Reconciliation 2023
 
  2022
 
Tangible book value per common share          
Total equity $ 111,700     $ 109,055  
Intangible assets   (4,632 )     (4,648 )
Common tangible equity $ 107,068     $ 104,407  
Common shares outstanding   6,032       5,983  
Tangible book value per common share $ 17.75     $ 17.45  
           
Tangible common equity to tangible assets          
Tangible common equity $ 107,068     $ 104,407  
Tangible assets   1,399,085       1,323,767  
Tangible common equity to tangible assets ratio   7.65 %     7.89 %
           
Tangible common equity to tangible assets, adjusted          
Tangible common equity $ 107,068     $ 104,407  
Tangible assets   1,399,085       1,323,767  
Less: Paycheck Protection Program (PPP) loans         (13,292 )
Total assets excluding PPP loans $ 1,399,085     $ 1,310,475  
Tangible common equity to tangible assets ratio, excluding PPP loans   7.65 %     7.97 %
               

* Basic and diluted earnings per share are calculated based upon the two-class method for the three months ended March 31, 2023 and 2022. 
Weighted average shares outstanding do not include unallocated ESOP shares.

The above information is preliminary and based on the Company’s data available at the time of presentation.

PATHFINDER BANCORP, INC.

FINANCIAL HIGHLIGHTS

(Dollars and shares in thousands except per share amounts)

The following table sets forth information concerning average interest-earning assets and interest-bearing liabilities and the yields and rates thereon. Interest income and resultant yield information in the table has not been adjusted for tax equivalency. Averages are computed on the daily average balance for each month in the period divided by the number of days in the period. Yields and amounts earned include loan fees. Nonaccrual loans have been included in interest-earning assets for purposes of these calculations.

  For the three months ended March 31,
  (Unaudited)
    2023       2022  
                Average                   Average  
    Average           Yield /       Average           Yield /  
(Dollars in thousands)   Balance       Interest   Cost       Balance       Interest   Cost  
Interest-earning assets:                      
Loans $ 899,258     $ 10,658   4.74 %   $ 845,461     $ 8,692   4.11 %
Taxable investment securities   368,437       3,825   4.15 %     329,291       2,168   2.63 %
Tax-exempt investment securities   36,480       455   4.99 %     32,721       118   1.44 %
Fed funds sold and interest-earning deposits   14,163       105   2.97 %     31,830       4   0.05 %
Total interest-earning assets   1,318,338       15,043   4.56 %     1,239,303       10,982   3.54 %
Noninterest-earning assets:                      
Other assets   101,194               91,622          
Allowance for credit losses   (17,061 )             (13,031 )        
Net unrealized losses on available-for-sale securities   (12,529 )             (1,334 )        
Total assets $ 1,389,942             $ 1,316,560          
Interest-bearing liabilities:                      
NOW accounts $ 97,796     $ 91   0.37 %   $ 106,894     $ 71   0.27 %
Money management accounts   15,300       4   0.10 %     16,072       4   0.10 %
MMDA accounts   261,594       1,275   1.95 %     261,898       246   0.38 %
Savings and club accounts   133,532       64   0.19 %     138,585       48   0.14 %
Time deposits   454,980       2,603   2.29 %     377,907       596   0.63 %
Subordinated loans   29,748       472   6.35 %     29,578       412   5.57 %
Borrowings   86,761       566   2.61 %     63,528       138   0.87 %
Total interest-bearing liabilities   1,079,711       5,075   1.88 %     994,462       1,515   0.61 %
Noninterest-bearing liabilities:                      
Demand deposits   180,845               199,164          
Other liabilities   16,403               11,904          
Total liabilities   1,276,959               1,205,530          
Shareholders’ equity   112,983               111,030          
Total liabilities & shareholders’ equity $ 1,389,942             $ 1,316,560          
Net interest income     $ 9,968           $ 9,467    
Net interest rate spread         2.68 %           2.93 %
Net interest margin         3.02 %           3.06 %
Ratio of average interest-earning assets to average interest-bearing liabilities         122.10 %           124.62 %
                           

The above information is preliminary and based on the Company’s data available at the time of presentation.

PATHFINDER BANCORP, INC.

FINANCIAL HIGHLIGHTS

(Dollars and shares in thousands except per share amounts)

Net interest income can also be analyzed in terms of the impact of changing interest rates on interest-earning assets and interest bearing liabilities, and changes in the volume or amount of these assets and liabilities. The following table represents the extent to which changes in interest rates and changes in the volume of interest-earning assets and interest-bearing liabilities have affected the Company’s interest income and interest expense during the years indicated. Information is provided in each category with respect to: (i) changes attributable to changes in volume (change in volume multiplied by prior rate); (ii) changes attributable to changes in rate (changes in rate multiplied by prior volume); and (iii) total increase or decrease. Changes attributable to both rate and volume have been allocated ratably. Tax-exempt securities have not been adjusted for tax equivalency.

  (Unaudited)
  Three months ended March 31,
  2023 vs. 2022
  Increase/(Decrease) due to
              Total
              Increase
(In thousands) Volume   Rate   (Decrease)
Interest Income:              
Loans $ 576     $ 1,390     $ 1,966  
Taxable investment securities   282       1,375       1,657  
Tax-exempt investment securities   15       322       337  
Interest-earning deposits   (17 )     118       101  
Total interest income   856       3,205       4,061  
Interest Expense:              
NOW accounts   (36 )     56       20  
Money management accounts   (1 )     1        
MMDA accounts   (2 )     1,031       1,029  
Savings and club accounts   (11 )     27       16  
Time deposits   145       1,862       2,007  
Subordinated loans   2       58       60  
Borrowings   66       362       428  
Total interest expense   163       3,397       3,560  
Net change in net interest income $ 693     $ (192 )   $ 501  
                       

The above information is preliminary and based on the Company’s data available at the time of presentation.


Investor/Media Contacts


James A. Dowd, President, CEO
Walter F. Rusnak, Senior Vice President, CFO
Telephone: (315) 343-0057



MeridianLink® Reports First Quarter 2023 Results

MeridianLink® Reports First Quarter 2023 Results

Revenue of $77.1 million grows 6%year-over-year

COSTA MESA, Calif.–(BUSINESS WIRE)–
MeridianLink, Inc. (NYSE: MLNK), a leading provider of modern software platforms for financial institutions and consumer reporting agencies, today announced financial results for the first quarter ended March 31, 2023.

“Our solid first quarter revenue performance highlights the continued strength of our multi-product platform, MeridianLink® One,” said Nicolaas Vlok, chief executive officer of MeridianLink. “There is strong demand for the cross-sell power and configurability of the platform to create seamless digital lending experiences. With that ongoing demand, our revenue grew 6% year-over-year to $77.1 million, and lending software solutions revenue grew 18% year-over-year to $58.0 million, now accounting for 75% of total revenue. Given the macro backdrop, we believe this performance is a fantastic achievement that could not have been done without the dedication of the entire MeridianLink team.”

Quarterly Financial Highlights:

  • Revenue of $77.1 million, an increase of 6% year-over-year

  • Operating income of $1.7 million, or 2% of revenue and Non-GAAP operating income of $9.9 million, or 13% of revenue

  • Net loss of $(5.7) million, or (7)% of revenue, and Adjusted EBITDA of $24.9 million, or 32% of revenue

  • Cash flows from operations of $67.8 million and free cash flow of $58.3 million for the last twelve month period

Business and Operating Highlights:

  • MeridianLink welcomed Suresh Balasubramanian as our new Chief Marketing Officer and Dean Germeyer as our new Chief Customer Officer. With this added leadership expertise, we are bolstering our ability to capture more share in the market and engage more deeply with customers across our support, services, and customer success teams.

  • The Company announced another strong roster of new logo and cross-sell wins. A financial holding company chose MeridianLink One to configure the multiple lending needs of its sub banks on a unified platform; FedChoice Federal Credit Union added MeridianLink® Insight to make faster, well-informed business decisions to improve its member experience; and a global fintech partner leveraged MeridianLink® Consumer to quickly launch its credit card offering at scale.

  • MeridianLink enhanced our MeridianLink® Collect integration with SWBC to provide a more automated, modern collections strategy to customers in the midst of demanding financial conditions.

  • In response to evolving customer needs, MeridianLink launched a new comprehensive deposit growth solution through the integration of MeridianLink® Engage and MeridianLink® Opening. With relevant, personalized communications and frictionless account opening, customers can quickly capture more deposit opportunities.

Business Outlook

Based on information as of today, May 2, 2023, the Company issues second quarter financial guidance and updates full year 2023 financial guidance as follows:

Second Quarter Fiscal 2023:

  • Revenue is expected to be in the range of $76.0 million to $79.0 million

  • Adjusted EBITDA is expected to be in the range of $27.0 million to $30.0 million

Full Year 2023:

  • Revenue is expected to be in the range of $307.0 million to $313.0 million

  • Adjusted EBITDA is expected to be in the range of $109.0 million to $115.0 million

Conference Call Information

MeridianLink will hold a conference call to discuss our first quarter results today, May 2, 2023, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). The conference call can be accessed by dialing (888) 396-8049 from North America toll-free or the Participant Local number of (416) 764-8646 with Conference ID 13121811. A live webcast of the conference call can be accessed from the investor relations page of MeridianLink’s website at ir.meridianlink.com. An archived replay of the webcast will be available at the same website following the conclusion of the call. A telephonic replay will be available until 8:59 p.m. Pacific Time (11:59 p.m. Eastern Time) on Thursday, May 9, 2023, at (877) 674-7070 from North America or (416) 764-8692 as a Participant Local with Playback Passcode 121811.

About MeridianLink

MeridianLink® (NYSE: MLNK), headquartered in Costa Mesa, California, powers digital lending and account opening for financial institutions and provides data verification solutions for consumer reporting agencies. MeridianLink’s scalable, cloud-based platforms help customers build deeper relationships with consumers through data-driven, personalized experiences across the entire lending life cycle.

MeridianLink enables customers to accelerate revenue growth, reduce risk, and exceed consumer expectations through seamless digital experiences. Its partner marketplace supports hundreds of integrations for tailored innovation. For more than 20 years, MeridianLink has prioritized the democratization of lending for consumers, businesses, and communities. Learn more at www.meridianlink.com.

Non-GAAP Financial Measures

To supplement the financial measures presented in accordance with generally accepted accounting principles, or GAAP, we provide certain non-GAAP financial measures, such as adjusted EBITDA and adjusted EBITDA margin; non-GAAP operating income (loss); non-GAAP net income (loss); non-GAAP cost of revenue; non-GAAP sales and marketing expenses; non-GAAP research and development expenses; non-GAAP general and administrative expenses; and free cash flow. The presentation of these financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Rather, we believe that these non-GAAP financial measures, when viewed in addition to and not in lieu of our reported GAAP financial results, provide investors with additional meaningful information to assess our financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating our business. The following definitions are provided:

  • Non-GAAP operating income (loss): GAAP operating income (loss), excluding the impact of share-based compensation, employer payroll taxes on employee stock transactions, restructuring related costs, and sponsor and third-party acquisition-related costs.

  • Non-GAAP net income (loss): GAAP net income (loss), excluding the impact of share-based compensation, employer payroll taxes on employee stock transactions, restructuring related costs sponsor and third-party acquisition-related costs, and the effect of income taxes on non-GAAP items. The effects of income taxes on non-GAAP items reflect a fixed long-term projected tax rate of 24%.

    The Company employs a structural long-term projected non-GAAP income tax rate of 24% for greater consistency across reporting periods, eliminating effects of items not directly related to the Company’s operating structure that may vary in size and frequency. This long-term projected non-GAAP income tax rate is determined by analyzing a mix of historical and projected tax filing positions, assumes no additional acquisitions during the projection period, and takes into account various factors, including the Company’s anticipated tax structure, its tax positions in different jurisdictions, and current impacts from key U.S. legislation where the Company operates. We will reevaluate this tax rate, as necessary, for significant events such as significant alterations in the U.S. tax environment, substantial changes in the Company’s geographic earnings mix due to acquisition activity, or other shifts in the Company’s strategy or business operations.

  • Adjusted EBITDA: net income (loss) before interest expense, taxes, depreciation and amortization, share-based compensation expense, employer payroll taxes on employee stock transactions, restructuring related costs, sponsor and third-party acquisition related costs, and deferred revenue reductions from purchase accounting for acquisitions prior to the adoption of ASU 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers,” which we early adopted on January 1, 2022 on a prospective basis. As of March 31, 2023, the remaining deferred revenue from acquisitions prior to the adoption of ASU 2021-08 was less than $0.1 million, which will be recognized on a straight line basis through December 31, 2023.

  • Non-GAAP cost of revenue: GAAP cost of revenue, excluding the impact of share-based compensation, employer payroll taxes on employee stock transactions, and amortization of developed technology.

  • Non-GAAP operating expenses: GAAP operating expenses, excluding the impact of share-based compensation, employer payroll taxes on employee stock transactions, and depreciation and amortization, as applicable.

  • Free cash flow: GAAP cash flow from operating activities less GAAP purchases of property and equipment (Capital Expenditures) and capitalized costs related to developed technology (Capitalized Software).

Reconciliations to comparable GAAP financial measures are available in the accompanying schedules, which are posted as part of this earnings release on our website. No reconciliation is provided with respect to certain forward-looking non-GAAP financial measures as the GAAP measures are not accessible on a forward-looking basis. We cannot reliably predict all necessary components or their impact to reconcile such financial measures without unreasonable effort. The events necessitating a non-GAAP adjustment are inherently unpredictable and may have a significant impact on our future GAAP financial results.

Forward-Looking Statements

This release contains, and our above-referenced conference call and webcast will contain, statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Generally, these statements can be identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions, although not all forward-looking statements contain these identifying words. Further, statements describing our strategy, outlook, guidance, plans, intentions, or goals are also forward-looking statements. These forward-looking statements reflect our predictions, expectations, or forecasts, including, but not limited to, statements regarding, and guidance with respect to, our strategy, our future financial and operational performance, future economic conditions, our strategic initiatives, including anticipated benefits and integration of an acquisition, our restructuring plan, including expected associated timing, benefits, and costs, our development or delivery of new or enhanced solutions and anticipated results of those solutions for our customers, our market size and growth opportunities, our competitive positioning, projected costs, technological capabilities and plans, and objectives of management. Actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks related to our business and industry, as well as those set forth in Item 1A. Risk Factors, or elsewhere, in our Annual Report on Form 10-K for the most recently ended fiscal year, any updates in our Quarterly Reports on Form 10-Q filed for periods subsequent to such Form 10-K, and our other SEC filings. These forward-looking statements are based on reasonable assumptions as of the date hereof. The plans, intentions, or expectations disclosed in our forward-looking statements may not be achieved, and you should not rely upon forward-looking statements as predictions of future events. We undertake no obligation, other than as required by applicable law, to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Condensed Consolidated Balance Sheets

(unaudited)

(in thousands, except share and per share data)

 

 

As of

 

March 31, 2023

 

December 31, 2022

 

 

 

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

77,796

 

 

$

55,780

 

Accounts receivable, net

 

37,401

 

 

 

32,905

 

Prepaid expenses and other current assets

 

10,798

 

 

 

9,447

 

Escrow deposit

 

30,000

 

 

 

30,000

 

Total current assets

 

155,995

 

 

 

128,132

 

Property and equipment, net

 

3,891

 

 

 

4,245

 

Right of use assets

 

1,929

 

 

 

2,185

 

Intangible assets, net

 

285,412

 

 

 

297,475

 

Deferred tax assets, net

 

14,893

 

 

 

13,939

 

Goodwill

 

608,902

 

 

 

608,657

 

Other assets

 

4,784

 

 

 

4,524

 

Total assets

$

1,075,806

 

 

$

1,059,157

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

3,986

 

 

$

1,249

 

Accrued liabilities

 

34,102

 

 

 

32,500

 

Deferred revenue

 

34,090

 

 

 

16,945

 

Current portion of long-term debt, net of debt issuance costs

 

3,506

 

 

 

3,505

 

Total current liabilities

 

75,684

 

 

 

54,199

 

Long-term debt, net of debt issuance costs

 

422,526

 

 

 

423,404

 

Long-term deferred revenue

 

992

 

 

 

1,141

 

Other long-term liabilities

 

1,165

 

 

 

1,322

 

Total liabilities

 

500,367

 

 

 

480,066

 

Commitments and contingencies (Note 5)

 

 

 

Stockholders’ Equity

 

 

 

Preferred stock, $0.001 par value; 50,000,000 shares authorized; zero shares issued and outstanding at March 31, 2023 and December 31, 2022

 

 

 

 

 

Common stock, $0.001 par value; 600,000,000 shares authorized, 80,636,894 and 80,644,452 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively

 

132

 

 

 

128

 

Additional paid-in capital

 

626,905

 

 

 

621,396

 

Accumulated deficit

 

(51,598

)

 

 

(42,433

)

Total stockholders’ equity

 

575,439

 

 

 

579,091

 

Total liabilities and stockholders’ equity

$

1,075,806

 

 

$

1,059,157

 

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share data)

 

 

Three Months Ended March 31,

 

2023

 

2022

Revenues, net

$

77,135

 

 

$

72,754

 

Cost of revenues:

 

 

 

Subscription and services

 

23,501

 

 

 

21,104

 

Amortization of developed technology

 

4,454

 

 

 

3,434

 

Total cost of revenues

 

27,955

 

 

 

24,538

 

Gross profit

 

49,180

 

 

 

48,216

 

Operating expenses:

 

 

 

General and administrative

 

22,555

 

 

 

18,187

 

Research and development

 

13,812

 

 

 

8,409

 

Sales and marketing

 

8,213

 

 

 

4,743

 

Acquisition related costs

 

 

 

 

2,283

 

Restructuring related costs

 

2,904

 

 

 

 

Total operating expenses

 

47,484

 

 

 

33,622

 

Operating (loss) income

 

1,696

 

 

 

14,594

 

Other (income) expense, net:

 

 

 

Other income

 

(470

)

 

 

(163

)

Interest expense, net

 

9,031

 

 

 

4,358

 

Total other expense, net

 

8,561

 

 

 

4,195

 

(Loss) income before (benefit from) provision for income taxes

 

(6,865

)

 

 

10,399

 

 

 

 

 

(Benefit from) provision for income taxes

 

(1,199

)

 

 

2,920

 

Net (loss) income

$

(5,666

)

 

$

7,479

 

 

 

 

 

Net (loss) income per share:

 

 

 

Basic

$

(0.07

)

 

$

0.09

 

Diluted

$

(0.07

)

 

$

0.09

 

Weighted average common stock outstanding:

 

 

 

Basic

 

80,659,978

 

 

 

79,974,071

 

Diluted

 

80,659,978

 

 

 

82,228,936

 

Net Revenues by Major Source

(unaudited)

(in thousands)

 

 

Three Months Ended March 31,

 

2023

 

2022

Subscription fees

$

66,405

 

$

63,469

Professional services

 

8,435

 

 

 

7,112

 

Other

 

2,295

 

 

 

2,173

 

Total

$

77,135

 

 

$

72,754

 

Net Revenues by Solution Type

(unaudited)

(in thousands)

 

 

Three Months Ended March 31,

 

2023

 

2022

Lending software solutions

$

58,001

 

 

$

49,167

 

Data verification software solutions

 

19,134

 

 

 

23,587

 

Total (1)

$

77,135

 

 

$

72,754

 

% Growth attributable to:

 

 

 

Lending software solutions

 

12

%

 

 

Data verification software

 

(6

)%

 

 

Total % growth

 

6

%

 

 

 

 

 

 

(1) % Revenue related to mortgage loan market:

 

 

 

Lending software solutions

 

11

%

 

 

7

%

Data verification software

 

61

%

 

 

70

%

Total % revenue related to mortgage loan market

 

24

%

 

 

28

%

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

 

 

Three Months Ended March 31,

 

2023

 

2022

Cash flows from operating activities:

 

 

 

Net (loss) income

$

(5,666

)

 

$

7,479

 

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

14,531

 

 

 

12,905

 

Provision for expected credit losses

 

532

 

 

 

 

Amortization of debt issuance costs

 

235

 

 

 

484

 

Share-based compensation expense

 

4,891

 

 

 

3,808

 

Loss on disposal of fixed assets

 

 

 

 

135

 

Deferred income taxes

 

(1,198

)

 

 

2,679

 

Changes in operating assets and liabilities, net of acquisitions:

 

 

 

Accounts receivable

 

(5,028

)

 

 

(7,248

)

Prepaid expenses and other assets

 

(1,636

)

 

 

(460

)

Accounts payable

 

2,717

 

 

 

301

 

Accrued liabilities

 

1,706

 

 

 

194

 

Deferred revenue

 

16,997

 

 

 

14,586

 

Net cash provided by operating activities

 

28,081

 

 

 

34,863

 

Cash flows from investing activities:

 

 

 

Capitalized software additions

 

(1,924

)

 

 

(1,522

)

Purchases of property and equipment

 

(134

)

 

 

(419

)

Net cash used in investing activities

 

(2,058

)

 

 

(1,941

)

Cash flows from financing activities:

 

 

 

Repurchases of common stock

 

(3,490

)

 

 

 

Proceeds from exercise of stock options

 

594

 

 

 

179

 

Taxes paid related to net share settlement of RSUs

 

(24

)

 

 

 

Principal payments of long-term debt

 

(1,087

)

 

 

 

Net cash (used in) provided by financing activities

 

(4,007

)

 

 

179

 

Net increase in cash and cash equivalents

 

22,016

 

 

 

33,101

 

Cash and cash equivalents, beginning of period

 

55,780

 

 

 

113,645

 

Cash and cash equivalents, end of period

$

77,796

 

 

$

146,746

 

 

Supplemental disclosures of cash flow information:

 

 

 

Cash paid for interest

$

9,019

 

 

$

3,869

 

Cash paid for income taxes

 

50

 

 

 

44

 

Non-cash investing and financing activities:

 

 

 

Purchase price allocation adjustment related to income tax effects for StreetShares acquisition

$

245

 

 

$

 

Purchases of property and equipment included in accounts payable and accrued expenses

 

79

 

 

 

 

Share-based compensation expense capitalized to software additions

 

48

 

 

 

79

 

Excise taxes payable included in repurchases of common stock

 

9

 

 

 

 

Vesting of RSAs and RSUs

 

4

 

 

 

32

 

Initial recognition of operating lease liability

 

 

 

 

3,372

 

Initial recognition of operating lease right-of-use asset

 

 

 

 

2,627

 

Reconciliation from GAAP to Non-GAAP Results

(unaudited)

(in thousands, except share and per share data)

 

 

Three Months Ended March 31,

 

2023

 

2022

 

 

 

 

Operating income

$

1,696

 

 

$

14,594

 

Add: Share-based compensation expense

 

5,190

 

 

 

3,808

 

Add: Employer payroll taxes on employee stock transactions

 

126

 

 

 

145

 

Add: Restructuring related costs

 

2,904

 

 

 

 

Add: Sponsor and third-party acquisition related costs

 

 

 

 

2,288

 

Non-GAAP operating income

$

9,916

 

 

$

20,835

 

Operating margin

 

2

%

 

 

20

%

Non-GAAP operating margin

 

13

%

 

 

29

%

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

2023

 

2022

 

 

 

 

Net (loss) income

$

(5,666

)

 

$

7,479

 

Add: Share-based compensation expense

 

5,190

 

 

 

3,808

 

Add: Employer payroll taxes on employee stock transactions

 

126

 

 

 

145

 

Add: Restructuring related costs

 

2,904

 

 

 

 

Add: Sponsor and third-party acquisition related costs

 

 

 

 

2,288

 

Add: Income tax effect on non-GAAP items

 

(1,973

)

 

 

(1,498

)

Non-GAAP net (loss) income

$

581

 

 

$

12,222

 

Non-GAAP basic net (loss) income per share

$

0.01

 

 

$

0.15

 

Non-GAAP diluted net (loss) income per share

 

0.01

 

 

 

0.15

 

Weighted average shares used to compute Non-GAAP basic net income per share

 

80,659,978

 

 

 

79,974,071

 

Weighted average shares used to compute Non-GAAP diluted net income per share

 

82,538,596

 

 

 

82,228,936

 

Net (loss) income margin

 

(7

)%

 

 

10

%

Non-GAAP net income margin

 

1

%

 

 

17

%

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

2023

 

2022

 

 

 

 

Net (loss) income

$

(5,666

)

 

$

7,479

 

Interest expense

 

9,031

 

 

 

4,358

 

Taxes

 

(1,199

)

 

 

2,920

 

Depreciation and amortization

 

14,531

 

 

 

12,905

 

Share-based compensation expense

 

5,190

 

 

 

3,808

 

Employer payroll taxes on employee stock transactions

 

126

 

 

 

145

 

Restructuring related costs

 

2,904

 

 

 

 

Sponsor and third-party acquisition related costs

 

 

 

 

2,288

 

Deferred revenue reduction from purchase accounting for acquisitions prior to 2022

 

20

 

 

 

62

 

Adjusted EBITDA

$

24,937

 

 

$

33,965

 

Net (loss) income margin

 

(7

)%

 

 

10

%

Adjusted EBITDA margin

 

32

%

 

 

47

%

Reconciliation from GAAP to Non-GAAP Results

(unaudited)

(in thousands)

 

 

Three Months Ended March 31,

 

2023

 

2022

 

 

 

 

Cost of revenue

$

27,955

 

 

$

24,538

 

Less: Share-based compensation expense

 

853

 

 

 

965

 

Less: Employer payroll taxes on employee stock transactions

 

22

 

 

 

54

 

Less: Amortization of developed technology

 

4,454

 

 

 

3,434

 

Non-GAAP cost of revenue

$

22,626

 

 

$

20,085

 

Cost of revenue as a % of revenue

 

36

%

 

 

34

%

Non-GAAP cost of revenue as a % of revenue

 

29

%

 

 

28

%

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

2023

 

2022

 

 

 

 

General and administrative

$

22,555

 

 

$

18,187

 

Less: Share-based compensation expense

 

2,264

 

 

 

1,381

 

Less: Employer payroll taxes on employee stock transactions

 

51

 

 

 

32

 

Less: Depreciation expense

 

495

 

 

 

561

 

Less: Amortization of intangibles

 

9,582

 

 

 

8,910

 

Non-GAAP general & administrative

$

10,163

 

 

$

7,303

 

General and administrative as a % of revenue

 

29

%

 

 

25

%

Non-GAAP general and administrative as a % of revenue

 

13

%

 

 

10

%

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

2023

 

2022

 

 

 

 

Research and development

$

13,812

 

 

$

8,409

 

Less: Share-based compensation expense

 

1,783

 

 

 

1,077

 

Less: Employer payroll taxes on employee stock transactions

 

27

 

 

 

40

 

Non-GAAP research and development

$

12,002

 

 

$

7,292

 

Research and development as a % of revenue

 

18

%

 

 

12

%

Non-GAAP research and development as a % of revenue

 

16

%

 

 

10

%

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

2023

 

2022

 

 

 

 

Sales and marketing

$

8,213

 

 

$

4,743

 

Less: Share-based compensation expense

 

290

 

 

 

385

 

Less: Employer payroll taxes on employee stock transactions

 

26

 

 

 

19

 

Non-GAAP sales and marketing

$

7,897

 

 

$

4,339

 

Sales and marketing as a % of revenue

 

11

%

 

 

7

%

Non-GAAP sales and marketing as a % of revenue

 

10

%

 

 

6

%

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

2023

 

2022

 

 

 

 

Net cash provided by operating activities

$

28,081

 

 

$

34,863

 

Less: Capitalized software

 

1,924

 

 

 

1,522

 

Less: Capital expenditures

 

134

 

 

 

419

 

Free cash flow

$

26,023

 

 

$

32,922

 

 

Press Contact

Becky Frost

(714) 784-5839

[email protected]

Investor Relations Contact

Erik Schneider

(714) 332-6357

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Payments Technology Software Finance Fintech Banking

MEDIA:

Logo
Logo

UFP Industries Announces First Quarter Results

UFP Industries Announces First Quarter Results

Net sales of $1.82 billion, diluted EPS of $1.98

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–
UFP Industries, Inc. (Nasdaq: UFPI) today announced first quarter 2023 results including net sales of $1.82 billion, net earnings attributable to controlling interest of $126 million, and earnings per diluted share of $1.98.

“Given the softer economy and general uncertainty in the markets, these results are in line with our expectations and, in some instances, better than we anticipated, thanks to the hard work of our UFP teammates,” said Chairman and CEO Matthew J. Missad. “Our experienced team continues to provide excellent value to our customers while efficiently managing the business with a determination to deliver strong results for our shareholders. Our strong cash flow, excellent balance sheet and prudent capital allocation enable us to take advantage of opportunities that may become available during this cycle. Of course, our operations will continue to make sure we are sized correctly for current demand, while still investing in product and service enhancements and innovations to create value for our customers. Our outlook remains positive, albeit at a lower level than 2021 and 2022.”

First Quarter 2023 Highlights (comparisons on a year-over-year basis):

  • Net sales of $1.82 billion decreased 27 percent due to a 20 percent decrease in prices, an 8 percent decrease in organic unit sales, and a 1 percent increase in sales from acquisitions.

  • New product sales of $167 million decreased 10 percent, largely due to lower lumber prices. New product sales as a percent of total sales rose to 9.1 percent from 7.4 percent in 2022.

  • Adjusted EBITDA of $202 million decreased 31 percent, and adjusted EBITDA margin dropped to 11.1 percent from 11.7 percent in 2022.

  • Diluted EPS of $1.98 represents a 34 percent decrease from last year.

Capital Allocation

UFP Industries maintains a strong balance sheet, with $145.3 million in net surplus cash (surplus cash less interest-bearing debt and cash overdraft) on April 1, 2023, compared to $409.8 million in net debt at the end of the first quarter of 2022. The company had approximately $1.7 billion of liquidity as of April 1, 2023. The company’s return-focused approach to capital allocation includes the following:

– A target of $200 million for capital investments in 2023, including value-added growth investments and significant investments in robotics, automation and technology.

– Repurchases of approximately 451,000 shares of common stock for $35.3 million during the first quarter of 2023 (at an average price of $78.27 per share). The company is authorized to purchase an additional 1.5 million shares through February 3, 2024, and intends to continue to repurchase UFPI shares when the price is advantageous and to offset dilution resulting from long-term, share-based incentive compensation programs.

– A quarterly dividend payment of $0.25 per share, approved by the board of directors on April 26, 2023, payable on June 15, 2023, to shareholders of record on June 1, 2023.

The company continues to seek strategic acquisitions that drive long-term growth and margin improvements, enhance its capabilities, and create incremental value for its customers and shareholders.

By business segment, the company reported the following first-quarter 2023 results:

UFP Retail Solutions

$749.6 million in net sales, down 25 percent compared to the first quarter of 2022, due to a 23 percent decline in selling prices (due to the relative decrease in the lumber market) and a 2 percent decline in organic unit sales. Gross profit decreased 30 percent to $94.4 million, primarily due to the impact of products sold with a variable price. Those products benefited from a significant increase in lumber prices during the first quarter of 2022. Based on anticipated lumber prices, the company expects more favorable comparisons for the second quarter of 2023 over 2022.

UFP Packaging (formerly UFP Industrial)

$486.6 million in net sales, down 20 percent compared to the first quarter of 2022, due to an 18 percent decrease in selling prices, a 4 percent decline in organic unit sales, and a 2 percent increase in sales from acquisitions. Gross profit decreased 19 percent to $120.9 million due to normalizing market pricing and a small decline in volume.

UFP Construction

$515.6 million in net sales, down 34 percent compared to the first quarter of 2022, due to an 18 percent decrease in selling prices and a 16 percent decrease in organic unit sales. Gross profit decreased 25 percent to $121.7 million, largely due to normalizing market pricing and a decline in volume among residential and manufactured housing customers in line with market conditions.

CONFERENCE CALL

UFP Industries will conduct a conference call to discuss its outlook and information included in this news release at 4:30 p.m. ET on Tuesday, May 2, 2023. The call will be hosted by Chairman and CEO Matthew J. Missad and CFO Michael Cole and will be available simultaneously and in its entirety to all interested investors and news media through a webcast at http://www.ufpi.com. A replay of the call will be available through the website.

UFP Industries, Inc.

UFP Industries is a holding company whose operating subsidiaries – UFP Packaging, UFP Construction and UFP Retail Solutions – manufacture, distribute and sell a wide variety of value-added products used in residential and commercial construction, packaging and other industrial applications worldwide. Founded in 1955, the company is headquartered in Grand Rapids, Mich., with affiliates in North America, Europe, Asia and Australia. UFP Industries is ranked #401 on the Fortune 500 and #149 on Industry Week’s list of America’s Largest Manufacturers. For more about UFP Industries, go to www.ufpi.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act, as amended, that are based on management’s beliefs, assumptions, current expectations, estimates and projections about the markets we serve, the economy and the Company itself. Words like “anticipates,” “believes,” “confident,” “estimates,” “expects,” “forecasts,” “likely,” “plans,” “projects,” “should,” variations of such words, and similar expressions identify such forward-looking statements. These statements do not guarantee future performance and involve certain risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood and degree of occurrence. The Company does not undertake to update forward-looking statements to reflect facts, circumstances, events, or assumptions that occur after the date the forward-looking statements are made. Actual results could differ materially from those included in such forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainty. Among the factors that could cause actual results to differ materially from forward-looking statements are the following: fluctuations in the price of lumber; adverse or unusual weather conditions; adverse economic conditions in the markets we serve; government regulations, particularly involving environmental and safety regulations; and our ability to make successful business acquisitions. Certain of these risk factors as well as other risk factors and additional information are included in the Company’s reports on Form 10-K and 10-Q on file with the Securities and Exchange Commission

Non-GAAP Financial Information

This release includes certain financial information not prepared in accordance with U.S. GAAP. Because not all companies calculate non-GAAP financial information identically (or at all), the presentations herein may not be comparable to other similarly titled measures used by other companies. Management considers Adjusted EBITDA, a non-GAAP measure, an alternative performance measure which may provide useful information to investors.

Net earnings

Net earnings refers to net earnings attributable to controlling interest unless specifically noted.

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME (UNAUDITED)

FOR THE THREE MONTHS ENDED

MARCH 2023/2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Period and Year to Date

(In thousands, except per share data)

 

2023

2022

NET SALES

 

$

1,822,476

 

 

100.0

 

%

$

2,489,313

 

 

100.0

 

%

 

 

 

 

 

 

 

 

 

 

 

 

COST OF GOODS SOLD

 

 

1,464,147

 

 

80.3

 

 

 

2,010,950

 

 

80.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

 

358,329

 

 

19.7

 

 

 

478,363

 

 

19.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

 

 

194,683

 

 

10.7

 

 

 

220,150

 

 

8.8

 

 

OTHER LOSSES (GAINS), NET

 

 

1,938

 

 

0.1

 

 

 

(812

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EARNINGS FROM OPERATIONS

 

 

161,708

 

 

8.9

 

 

 

259,025

 

 

10.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

INTEREST AND OTHER

 

 

(2,841

)

 

(0.2

)

 

 

4,910

 

 

0.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EARNINGS BEFORE INCOME TAXES

 

 

164,549

 

 

9.0

 

 

 

254,115

 

 

10.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

INCOME TAXES

 

 

38,971

 

 

2.1

 

 

 

60,984

 

 

2.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET EARNINGS

 

 

125,578

 

 

6.9

 

 

 

193,131

 

 

7.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LESS NET LOSS (EARNINGS) ATTRIBUTABLE TO NONCONTROLLING INTEREST

 

 

491

 

 

 

 

 

(3,428

)

 

(0.1

)

 

 

 

 

 

 

 

 

 

 

 

 

 

NET EARNINGS ATTRIBUTABLE TO CONTROLLING INTEREST

 

$

126,069

 

 

6.9

 

 

$

189,703

 

 

7.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EARNINGS PER SHARE – BASIC

 

$

2.01

 

 

 

 

$

3.01

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EARNINGS PER SHARE – DILUTED

 

$

1.98

 

 

 

 

$

3.00

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COMPREHENSIVE INCOME

 

$

131,830

 

 

 

 

$

196,315

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LESS COMPREHENSIVE INCOME ATTRIBUTABLE TO NONCONTROLLING INTEREST

 

 

(1,760

)

 

 

 

 

(4,377

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

COMPREHENSIVE INCOME ATTRIBUTABLE TO CONTROLLING INTEREST

 

$

130,070

 

 

 

 

$

191,938

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS BY SEGMENT (UNAUDITED)

FOR THE THREE MONTHS ENDED

MARCH 2023/2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Period and Year to Date

 

 

2023

(In thousands)

 

Retail

 

Packaging

 

Construction

 

All Other

 

Corporate

 

Total

NET SALES

 

$

749,577

 

$

486,561

 

 

$

515,593

 

$

67,512

 

$

3,233

 

 

$

1,822,476

COST OF GOODS SOLD

 

 

655,139

 

 

365,663

 

 

 

393,934

 

 

47,876

 

 

1,535

 

 

 

1,464,147

GROSS PROFIT

 

 

94,438

 

 

120,898

 

 

 

121,659

 

 

19,636

 

 

1,698

 

 

 

358,329

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

 

 

53,355

 

 

66,252

 

 

 

67,338

 

 

13,522

 

 

(5,784

)

 

 

194,683

OTHER

 

 

27

 

 

(86

)

 

 

73

 

 

2,080

 

 

(156

)

 

 

1,938

EARNINGS FROM OPERATIONS

 

$

41,056

 

$

54,732

 

 

$

54,248

 

$

4,034

 

$

7,638

 

 

$

161,708

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Period and Year to Date

 

 

2022

(In thousands)

 

Retail

 

Packaging

 

Construction

 

All Other

 

Corporate

 

Total

NET SALES

 

$

993,232

 

$

611,369

 

 

$

786,471

 

$

95,567

 

$

2,674

 

 

$

2,489,313

 

COST OF GOODS SOLD

 

 

858,895

 

 

461,815

 

 

 

625,059

 

 

64,024

 

 

1,157

 

 

 

2,010,950

 

GROSS PROFIT

 

 

134,337

 

 

149,554

 

 

 

161,412

 

 

31,543

 

 

1,517

 

 

 

478,363

 

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

 

 

62,668

 

 

67,231

 

 

 

82,337

 

 

16,625

 

 

(8,711

)

 

 

220,150

 

OTHER

 

 

272

 

 

(68

)

 

 

257

 

 

103

 

 

(1,376

)

 

 

(812

)

EARNINGS FROM OPERATIONS

 

$

71,397

 

$

82,391

 

 

$

78,818

 

$

14,815

 

$

11,604

 

 

$

259,025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ADJUSTED EBITDA RECONCILIATION BY SEGMENT (UNAUDITED)

FOR THE THREE MONTHS ENDED

MARCH 2023/2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Period and Year to Date

 

 

2023

(In thousands)

 

Retail

 

Packaging

 

Construction

 

All Other

 

Corporate

 

Total

Net earnings

 

$

31,316

 

 

$

41,325

 

 

$

41,404

 

 

$

4,688

 

 

$

6,845

 

 

$

125,578

 

Interest and other

 

 

21

 

 

 

583

 

 

 

(5

)

 

 

(2,109

)

 

 

(1,331

)

 

 

(2,841

)

Income taxes

 

 

9,719

 

 

 

12,824

 

 

 

12,849

 

 

 

1,455

 

 

 

2,124

 

 

 

38,971

 

Expenses associated with share-based compensation arrangements

 

 

1,615

 

 

 

2,096

 

 

 

2,121

 

 

 

278

 

 

 

3,527

 

 

 

9,637

 

Net loss (gain) on disposition and impairment of assets

 

 

36

 

 

 

(86

)

 

 

(47

)

 

 

(10

)

 

 

(57

)

 

 

(164

)

Depreciation expense

 

 

5,618

 

 

 

7,682

 

 

 

4,628

 

 

 

615

 

 

 

7,231

 

 

 

25,774

 

Amortization of intangibles

 

 

1,055

 

 

 

2,246

 

 

 

797

 

 

 

532

 

 

 

379

 

 

 

5,009

 

Adjusted EBITDA

 

$

49,380

 

 

$

66,670

 

 

$

61,747

 

 

$

5,449

 

 

$

18,718

 

 

$

201,964

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA as a Percentage of Net Sales

 

 

6.6

%

 

 

13.7

%

 

 

12.0

%

 

 

8.1

%

 

 

579.0

%

 

 

11.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter Period and Year to Date

 

 

2022

(In thousands)

 

Retail

 

Packaging

 

Construction

 

All Other

 

Corporate

 

Total

Net earnings

 

$

54,246

 

 

$

62,228

 

 

$

59,903

 

 

$

10,611

 

 

$

6,143

 

 

$

193,131

 

Interest and other

 

 

23

 

 

 

512

 

 

 

 

 

 

854

 

 

 

3,521

 

 

 

4,910

 

Income taxes

 

 

17,128

 

 

 

19,651

 

 

 

18,915

 

 

 

3,350

 

 

 

1,940

 

 

 

60,984

 

Expenses associated with share-based compensation arrangements

 

 

1,221

 

 

 

1,408

 

 

 

1,464

 

 

 

224

 

 

 

2,614

 

 

 

6,931

 

Net loss (gain) on disposition and impairment of assets

 

 

305

 

 

 

(65

)

 

 

(11

)

 

 

10

 

 

 

(545

)

 

 

(306

)

Depreciation expense

 

 

4,436

 

 

 

6,807

 

 

 

3,434

 

 

 

572

 

 

 

6,593

 

 

 

21,842

 

Amortization of intangibles

 

 

883

 

 

 

1,715

 

 

 

864

 

 

 

1,082

 

 

 

128

 

 

 

4,672

 

Adjusted EBITDA

 

$

78,242

 

 

$

92,256

 

 

$

84,569

 

 

$

16,703

 

 

$

20,394

 

 

$

292,164

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA as a Percentage of Net Sales

 

 

7.9

%

 

 

15.1

%

 

 

10.8

%

 

 

17.5

%

 

 

762.7

%

 

 

11.7

%

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

MARCH 2023/2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(In thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

2023

 

 

2022

 

LIABILITIES AND EQUITY

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

423,299

 

$

73,783

 

Cash Overdraft

 

$

 

$

61,711

 

Restricted cash

 

 

761

 

 

729

 

Accounts payable

 

 

277,989

 

 

425,956

 

Investments

 

 

37,534

 

 

35,465

 

Accrued liabilities and other

 

 

249,350

 

 

372,640

 

Accounts receivable

 

 

809,389

 

 

1,095,362

 

Current portion of debt

 

 

3,020

 

 

42,895

 

Inventories

 

 

960,338

 

 

1,230,351

 

 

 

 

 

 

 

 

 

Other current assets

 

 

35,692

 

 

36,727

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL CURRENT ASSETS

 

 

2,267,013

 

 

2,472,417

 

TOTAL CURRENT LIABILITIES

 

 

530,359

 

 

903,202

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OTHER ASSETS

 

 

242,541

 

 

155,438

 

LONG-TERM DEBT AND FINANCE LEASE OBLIGATIONS

 

 

275,002

 

 

379,015

 

INTANGIBLE ASSETS, NET

 

 

487,080

 

 

445,232

 

OTHER LIABILITIES

 

 

178,986

 

 

173,577

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TEMPORARY EQUITY

 

 

6,801

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PROPERTY, PLANT AND EQUIPMENT, NET

 

 

700,155

 

 

600,879

 

SHAREHOLDERS’ EQUITY

 

 

2,705,641

 

 

2,218,172

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

3,696,789

 

$

3,673,966

 

TOTAL LIABILITIES AND EQUITY

 

$

3,696,789

 

$

3,673,966

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

FOR THE THREE MONTHS ENDED

MARCH 2023/2022

 

 

 

 

 

 

 

 

 

(In thousands)

 

2023

2022

CASH FLOWS USED IN OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net earnings

 

$

125,578

 

 

 

$

193,131

 

 

Adjustments to reconcile net earnings to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

25,774

 

 

 

 

21,842

 

 

Amortization of intangibles

 

 

5,009

 

 

 

 

4,672

 

 

Expense associated with share-based and grant compensation arrangements

 

 

9,637

 

 

 

 

6,931

 

 

Deferred income taxes (credit)

 

 

(242

)

 

 

 

101

 

 

Unrealized (gain) loss on investment and other

 

 

(149

)

 

 

 

1,601

 

 

Equity in loss of investee

 

 

588

 

 

 

 

515

 

 

Net gain on sale and disposition of assets

 

 

(164

)

 

 

 

(306

)

 

Changes in:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(191,064

)

 

 

 

(352,928

)

 

Inventories

 

 

14,674

 

 

 

 

(258,019

)

 

Accounts payable and cash overdraft

 

 

68,388

 

 

 

 

143,895

 

 

Accrued liabilities and other

 

 

(95,105

)

 

 

 

(6,466

)

 

NET CASH USED IN OPERATING ACTIVITIES

 

 

(37,076

)

 

 

 

(245,031

)

 

 

 

 

 

 

 

 

 

 

CASH FLOWS USED IN INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchases of property, plant, and equipment

 

 

(38,166

)

 

 

 

(32,072

)

 

Proceeds from sale of property, plant and equipment

 

 

319

 

 

 

 

1,207

 

 

Acquisitions, net of cash received and purchase of equity method investment

 

 

 

 

 

 

(24,571

)

 

Purchases of investments

 

 

(11,709

)

 

 

 

(6,030

)

 

Proceeds from sale of investments

 

 

8,849

 

 

 

 

4,725

 

 

Other

 

 

(1,151

)

 

 

 

(2,995

)

 

NET CASH USED IN INVESTING ACTIVITIES

 

 

(41,858

)

 

 

 

(59,736

)

 

 

 

 

 

 

 

 

 

 

CASH FLOWS (USED IN) FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Borrowings under revolving credit facilities

 

 

4,437

 

 

 

 

242,950

 

 

Repayments under revolving credit facilities

 

 

(4,518

)

 

 

 

(141,438

)

 

Repayments of debt

 

 

(29

)

 

 

 

(199

)

 

Contingent consideration payments and other

 

 

(6,179

)

 

 

 

(551

)

 

Proceeds from issuance of common stock

 

 

685

 

 

 

 

663

 

 

Dividends paid to shareholders

 

 

(15,642

)

 

 

 

(12,541

)

 

Distributions to noncontrolling interest

 

 

(4,859

)

 

 

 

(2,053

)

 

Repurchase of common stock

 

 

(33,288

)

 

 

 

(501

)

 

Other

 

 

25

 

 

 

 

 

 

NET CASH (USED IN) FROM FINANCING ACTIVITIES

 

 

(59,368

)

 

 

 

86,330

 

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash

 

 

2,739

 

 

 

 

1,726

 

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

(135,563

)

 

 

 

(216,711

)

 

 

 

 

 

 

 

 

 

 

ALL CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

 

 

559,623

 

 

 

 

291,223

 

 

 

 

 

 

 

 

 

 

 

ALL CASH AND CASH EQUIVALENTS, END OF PERIOD

 

$

424,060

 

 

 

$

74,512

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of cash and cash equivalents and restricted cash:

 

 

 

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

$

559,397

 

 

 

$

286,662

 

 

Restricted cash, beginning of period

 

 

226

 

 

 

 

4,561

 

 

All cash and cash equivalents, beginning of period

 

$

559,623

 

 

 

$

291,223

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents, end of period

 

$

423,299

 

 

 

$

73,783

 

 

Restricted cash, end of period

 

 

761

 

 

 

 

729

 

 

All cash and cash equivalents, end of period

 

$

424,060

 

 

 

$

74,512

 

 

 

 

 

 

 

 

 

 

 

 

Dick Gauthier

VP of Investor Relations

(616) 365-1555

KEYWORDS: Michigan United States North America

INDUSTRY KEYWORDS: Home Goods Building Systems Residential Building & Real Estate Retail Commercial Building & Real Estate Construction & Property Manufacturing Forest Products Other Retail Natural Resources Specialty Landscape Interior Design Packaging Architecture Other Construction & Property

MEDIA:

Logo
Logo

The Honest Company to Report First Quarter 2023 Financial Results on May 9, 2023

LOS ANGELES, May 02, 2023 (GLOBE NEWSWIRE) — The Honest Company (NASDAQ: HNST), a digitally-native consumer products company born in the Gen Z era to make purpose-driven consumer products designed for all people, today announced that it will report first quarter 2023 financial results before the market opens on Tuesday May 9, 2023.

The Company will host an investor conference call and webcast to review first quarter 2023 financial results at 9:00am PT/12:00pm ET on the same day. The live webcast can be accessed at https://investors.honest.com.   For those interested in participating in the conference call by phone, please go to this link: https://register.vevent.com/register/BI66d1af48f24e4029880f5cc0853b4dc2 and you will be provided with dial-in details directly to your registered email. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will remain available on the Company’s website for one year.

About The Honest Company

The Honest Company (NASDAQ: HNST) is a digitally-native consumer products company born in the Gen Z era to make purpose-driven consumer products designed for all people. Since its launch in 2012, Honest has been dedicated to creating thoughtfully formulated, safe and effective personal care, beauty, baby and household products, which are available via honest.com, third-party ecommerce partners and approximately 50,000 retail locations across the United States, Canada and Europe.   Based in Los Angeles, CA, the Company’s mission, to inspire everyone to love living consciously, is driven by its values of transparency, trust, sustainability and a deep sense of purpose around what matters most to its consumers: their health, their families and their homes. For more information about the Honest Standard and the company, please visit www.honest.com.

Investor Contacts:  
Steve Austenfeld
[email protected]                                                  

Elizabeth Bouquard
[email protected] 

Investor Inquiries:

[email protected]

Media Contact:                   
Jennifer Kroog Rosenberg
[email protected] 



Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments

  • Total revenues, which consist of net product revenues and collaboration revenues, for the first quarter 2023 totaled $253.5 million
  • Net product revenues for the first quarter 2023 totaled $231.5 million, a 23% increase over the same quarter of prior year

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2023.

“We are pleased to report another strong quarter of performance serving the Duchenne community. With EXONDYS 51, VYONDYS 53, and AMONDYS 45, we once again exceeded analyst estimates, with total revenue for the quarter reaching $253.5 million and net product revenue standing at $231.5 million and growing at 23% versus the same quarter of prior year. The Sarepta team has consistently performed and served the patient community over the last 6 years and it will be this team, with its track record of success, that will launch and serve the community in the United States with SRP-9001 if our BLA is approved,” said Doug Ingram, president and chief executive officer, Sarepta. “We look forward to sharing the totality of evidence supporting the safety and efficacy of SRP-9001 at the upcoming advisory committee meeting on May 12 and at the same time continuing to prepare for the launch of SRP-9001 in the United States.”

First Quarter 2023 and Recent Developments:

  • FDA advisory committee meeting for SRP-9001 to be held on May 12, 2023: In March, the Company announced that at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration’s Office of Therapeutic Products determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date. In April, Sarepta announced May 12, 2023 as the date of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 BLA. The advisory committee meeting will be hosted as a virtual meeting. SRP-9001 is Sarepta’s investigational gene therapy for the treatment of Duchenne muscular dystrophy.
  • SRP-5051-201 MOMENTUM Part B clinical trial fully enrolled: Sarepta has completed enrollment for Part B of the MOMENTUM clinical trial investigating the use of SRP-5051, the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO), to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. Data from Part B is expected in the second half of this year. If successful, Sarepta anticipates Part B to serve as the pivotal study for SRP-5051 and plans to seek accelerated approval for the candidate.
  • On track to complete enrollment in 2H23 for VOYAGENE clinical trial: VOYAGENE, or Study SRP-9003-201, is Sarepta’s phase 1 study of SRP-9003 (bidridistrogene xeboparvovec) for the treatment of limb-girdle muscular dystrophy Type 2E (LGMD2E). It is a U.S.-only study enrolling ambulant patients aged 18 years or older and non-ambulant patients aged 4 to 50 years old, using clinical process SRP-9003 material. The Company has already seen positive expression and functional data in their first clinical trial, SRP-9003-101, and is conducting VOYAGENE to gain insights into a broader patient population. Sarepta expects to complete enrollment for VOYAGENE in the second half of 2023 and to begin their phase 3 study using commercially representative process material by the end of this year.

Conference Call

The event will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

Financial Results

On a GAAP basis, for the three months ended March 31, 2023, the Company reported a net loss of $516.8 million, or $5.86 per basic and diluted share, compared to a net loss of $105.0 million reported for the same period of 2022, or $1.20 per basic and diluted share. This change is primarily due to the loss on debt extinguishment of $387.3 million incurred in the three months ended March 31, 2023, with no similar activity for the same period of 2022, as discussed in further detail below. On a non-GAAP basis, the net loss for the three months ended March 31, 2023 was $85.5 million, or $0.97 per basic and diluted share, compared to a net loss of $48.6 million, or $0.56 per basic and diluted share for the same period of 2022.

Revenues

For the three months ended March 31, 2023, the Company recorded total revenues of $253.5 million, which consist of net product revenues and collaboration revenues, compared to total revenues of $210.8 million for the same period of 2022, an increase of $42.7 million.

For the three months ended March 31, 2023, the Company recorded net product revenues of $231.5 million, compared to net product revenues of $188.8 million for the same period of 2022, an increase of $42.7 million. The increase primarily reflects the continuing increase in demand for the Company’s products.

For both the three months ended March 31, 2023 and 2022, the Company recognized $22.0 million of collaboration revenue, which relates to the F. Hoffman-La Roche Ltd. (Roche) collaboration arrangement.

Cost and Expenses

Cost of sales (excluding amortization of in-licensed rights)

For the three months ended March 31, 2023, cost of sales (excluding amortization of in-licensed rights) was $35.0 million, compared to $31.4 million for the same period of 2022, an increase of $3.6 million. The increase primarily reflects increasing demand for the Company’s products as well as the write-offs of certain batches of the Company’s products not meeting the Company’s quality specifications for the three months ended March 31, 2023, with no similar activity for the same period of 2022, partially offset by a decrease in royalty payments during the three months ended March 31, 2023 due to changes in the BioMarin Pharmaceuticals, Inc. (BioMarin) royalty terms.

Research and development

Research and development expenses were $245.7 million for the three months ended March 31, 2023, compared to $194.3 million for the same period of 2022, an increase of $51.4 million. The increase in research and development expenses primarily reflects the following:

  • $15.6 million increase in manufacturing expenses primarily due to a continuing ramp-up of the Company’s SRP-9001 manufacturing;

  • $14.0 million increase in compensation and other personnel expenses primarily due to changes in headcount;

  • $10.5 million increase in clinical trial expenses primarily due to an increased patient enrollment and site activation for the Company’s MOMENTUM and MIS51ON programs;

  • $6.5 million increase in research and other expenses primarily driven by an increase in sponsored research with academic institutions during the three months ended March 31, 2023 and an increase in lab-related expenses primarily due to changes in headcount;

  • $3.3 million increase in stock-based compensation expense primarily due to changes in headcount and the value of stock awards;

  • $2.8 million increase in facility- and technology-related expenses primarily due to the Company’s continuing expansion efforts;

  • $2.7 million increase in professional service expenses primarily due to an increase in reliance on third-party research and development contractors as the Company prepares for a potential launch of SRP-9001;

  • $1.5 million decrease in pre-clinical expenses primarily due to a decrease in toxicology study activity across multiple gene therapy and RNA platforms; and

  • $2.5 million increase in the offset to expense associated with a collaboration reimbursement from Roche due to continuing development of the Company’s SRP-9001 gene therapy programs.

Non-GAAP research and development expenses were $220.7 million and $173.2 million for the three months ended March 31, 2023 and 2022, respectively, an increase of $47.5 million.

Selling, general and administrative

Selling, general and administrative expenses were $110.7 million for the three months ended March 31, 2023, compared to $71.8 million for the same period in 2022, an increase of $38.9 million. The increase in selling, general and administrative expenses primarily reflects the following:

  • $17.8 million increase in professional service expenses primarily due to an increase in reliance on third-party selling, general and administrative contractors as the Company prepares for a potential launch of SRP-9001;

  • $11.0 million increase in compensation and other personnel expenses primarily due to changes in headcount;

  • $8.7 million increase in stock-based compensation expense primarily due to the Chief Executive Officer grant modification agreement executed in 2022, as well as changes in headcount and the value of stock awards; and

  • $1.7 million increase in facility- and technology-related expenses primarily due to the Company’s continuing expansion efforts.

Non-GAAP selling, general and administrative expenses were $83.3 million and $53.2 million for the three months ended March 31, 2023 and 2022, respectively, an increase of $30.1 million.

Amortization of in-licensed rights

For both the three months ended March 31, 2023 and 2022, the Company recorded amortization of in-licensed rights of approximately $0.2 million. This is related to the amortization of the in-licensed right assets recognized as a result of agreements the Company entered into with BioMarin and the University of Western Australia in July 2017 and April 2013, respectively.

Loss on debt extinguishment

On November 14, 2017, the Company issued $570.0 million aggregate principal amount of senior convertible notes due on November 15, 2024 (2024 Notes). On March 2, 2023, the Company entered into separate, privately negotiated exchange agreements with certain holders of the outstanding 2024 Notes (Exchange Agreements). The Exchange Agreements resulted in an exchange of $313.5 million in aggregate principal value of the 2024 Notes for shares of the Company’s common stock (2024 Notes Exchange). In connection with the 2024 Notes Exchange, the Company issued approximately 4.5 million shares of its common stock representing an agreed upon contractual exchange rate pursuant to the terms of each Exchange Agreement. The exchange was not pursuant to the conversion privileges included in the terms of the debt at issuance and therefore was accounted for as a debt extinguishment. The Company accounted for the debt extinguishment by recognizing the difference between the fair value of the shares of common stock transferred on the exchange date and the net carrying amount of the extinguished debt as a loss on debt extinguishment. The loss incurred on the extinguishment was $387.3 million, inclusive of $6.9 million in third-party debt conversion costs.

Other income (expense), net

For the three months ended March 31, 2023 and 2022, other income, net was $12.7 million and other expense, net was $17.3 million, respectively. The changes are primarily due to a $10.0 million increase in accretion of investment discount, net and a $9.1 million increase in interest income due to the investment mix of the Company’s investment portfolio, as well as a $9.5 million reduction of interest expense incurred as a result of the repayment of the December 2019 Term Loan in 2022.

Income tax expense

Income tax expense for the three months ended March 31, 2023 and 2022 was approximately $4.0 million and $0.9 million, respectively. Income tax expense for all periods presented relates to state and foreign income taxes.

Cash, Cash Equivalents, Restricted Cash and Investments

The Company had approximately $1.9 billion in cash, cash equivalents, investments and long-term restricted cash as of March 31, 2023 compared to $2.0 billion as of December 31, 2022. This decrease is driven by cash used to fund the Company’s ongoing operations during 2023.

Use of Non-GAAP Measures

In addition to the GAAP financial measures set forth in this press release, the Company has included certain non-GAAP measurements. The non-GAAP loss is defined by the Company as GAAP net loss excluding interest (income) expense, net, income tax expense, depreciation and amortization expense, stock-based compensation expense and other items. Non-GAAP research and development expenses are defined by the Company as GAAP research and development expenses excluding depreciation and amortization expense, stock-based compensation expense and other items. Non-GAAP selling, general and administrative expenses are defined by the Company as GAAP selling, general and administrative expenses excluding depreciation and amortization expense, stock-based compensation expense and other items.

1. Interest, tax, depreciation and amortization

Interest (income) expense, net amounts can vary substantially from period to period due to changes in cash and debt balances and interest rates driven by market conditions outside of the Company’s operations. Tax amounts can vary substantially from period to period due to tax adjustments that are not directly related to underlying operating performance. Depreciation expense can vary substantially from period to period as the purchases of property and equipment may vary significantly from period to period and without any direct correlation to the Company’s operating performance. Amortization expense primarily associated with in-licensed rights as well as patent costs are amortized over a period of several years after acquisition or patent application or renewal and generally cannot be changed or influenced by management.

2. Stock-based compensation expenses

Stock-based compensation expenses represent non-cash charges related to equity awards granted by the Company. Although these are recurring charges to operations, the Company believes the measurement of these amounts can vary substantially from period to period and depend significantly on factors that are not a direct consequence of operating performance that is within the Company’s control. Therefore, the Company believes that excluding these charges facilitates comparisons of the Company’s operational performance in different periods.

3. Other items

The Company evaluates other items of expense and income on an individual basis. It takes into consideration quantitative and qualitative characteristics of each item, including (a) nature, (b) whether the items relate to the Company’s ongoing business operations, and (c) whether the Company expects the items to continue on a regular basis. These other items include loss on debt extinguishment and impairment of equity investments.

  • The Company excludes from its non-GAAP results the loss on debt extinguishment, which is considered to be a non-recurring event as it is associated with a distinct financing decision and is not indicative of the performance of the Company’s core operations, which accordingly would make it difficult to compare the Company’s results to peer companies that also provide non-GAAP disclosures.

  • The Company excludes from its non-GAAP results the impairment of any equity investments as it is a non-cash item and is not considered to be a normal operating expense due to the variability of amount and lack of predictability as to the occurrence and/or timing of such impairments.

The Company uses these non-GAAP measures as key performance measures for the purpose of evaluating operational performance and cash requirements internally. The Company also believes these non-GAAP measures increase comparability of period-to-period results and are useful to investors as they provide a similar basis for evaluating the Company’s performance as is applied by management. These non-GAAP measures are not intended to be considered in isolation or to replace the presentation of the Company’s financial results in accordance with GAAP. Use of the terms non-GAAP research and development expenses, non-GAAP selling, general and administrative expenses, non-GAAP other income and loss adjustments, non-GAAP income tax expense, non-GAAP net loss, and non-GAAP basic and diluted net loss per share may differ from similar measures reported by other companies, which may limit comparability, and are not based on any comprehensive set of accounting rules or principles. All relevant non-GAAP measures are reconciled from their respective GAAP measures in the attached table “Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures.”

About EXONDYS 51

EXONDYS 51 (eteplirsen) uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion, or “skipping”, of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.

EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in some patients treated with EXONDYS 51. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.

EXONDYS 51 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.

Important Safety Information About EXONDYS 51

Hypersensitivity reactions, bronchospasm, chest pain, cough, tachycardia, and urticaria have occurred in patients who were treated with EXONDYS 51. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the EXONDYS 51 therapy.

Adverse reactions in Duchenne patients (N=8) treated with EXONDYS 51 30 mg or 50 mg/kg/week by intravenous (IV) infusion with an incidence of at least 25% more than placebo (N=4) (Study 1, 24 weeks) were (EXONDYS 51, placebo): balance disorder (38%, 0%), vomiting (38%, 0%) and contact dermatitis (25%, 0%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended.

The most common adverse reactions from observational clinical studies (N=163) seen in greater than 10% of the study population were headache, cough, rash, and vomiting.

For further information, please see the full Prescribing Information.

About VYONDYS 53

VYONDYS 53 (golodirsen) uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 53 of dystrophin pre-mRNA, resulting in exclusion, or “skipping,” of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.

VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.

VYONDYS 53 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.

Important Safety Information for VYONDYS 53

Hypersensitivity reactions, including rash, pyrexia, pruritus, urticaria, dermatitis, and skin exfoliation have occurred in VYONDYS 53-treated patients, some requiring treatment. If a hypersensitivity reaction occurs, institute appropriate medical treatment and consider slowing the infusion or interrupting the VYONDYS 53 therapy.

Kidney toxicity was observed in animals who received golodirsen. Although kidney toxicity was not observed in the clinical studies with VYONDYS 53, the clinical experience with VYONDYS 53 is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VYONDYS 53. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in Duchenne patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VYONDYS 53. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting VYONDYS 53. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months. Only urine expected to be free of excreted VYONDYS 53 should be used for monitoring of urine protein. Urine obtained on the day of VYONDYS 53 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any VYONDYS 53 that is excreted in the urine and thus lead to a false positive result for urine protein.

If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.

Adverse reactions observed in at least 20% of treated patients and greater than placebo were (VYONDYS 53, placebo): headache (41%, 10%), pyrexia (41%, 14%), fall (29%, 19%), abdominal pain (27%, 10%), nasopharyngitis (27%, 14%), cough (27%, 19%), vomiting (27%, 19%), and nausea (20%, 10%).

Other adverse reactions that occurred at a frequency greater than 5% of VYONDYS 53-treated patients and at a greater frequency than placebo were: administration site pain, back pain, pain, diarrhea, dizziness, ligament sprain, contusion, influenza, oropharyngeal pain, rhinitis, skin abrasion, ear infection, seasonal allergy, tachycardia, catheter site related reaction, constipation, and fracture.

For further information, please see the full Prescribing Information.

About AMONDYS 45

AMONDYS 45 (casimersen) uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to bind to exon 45 of dystrophin pre-mRNA, resulting in exclusion, or “skipping,” of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 45 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein.

AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping.

This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials.

AMONDYS 45 has met the full statutory standards for safety and effectiveness and as such is not considered investigational or experimental.

Important Safety Information for AMONDYS 45

AMONDYS 45 is contraindicated in patients with known hypersensitivity to casimersen or to any of the inactive ingredients. Instances of hypersensitivity, including angioedema and anaphylaxis, have occurred in patients receiving AMONDYS 45. If a hypersensitivity reaction occurs, institute appropriate medical treatment, and consider slowing the infusion, interrupting, or discontinuing the AMONDYS 45 infusion and monitor until the condition resolves.

Kidney toxicity was observed in animals who received casimersen. Although kidney toxicity was not observed in the clinical studies with AMONDYS 45, kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking AMONDYS 45. Because of the effect of reduced skeletal muscle mass on creatinine measurements, creatinine may not be a reliable measure of kidney function in Duchenne patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting AMONDYS 45. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting AMONDYS 45. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio (UPCR) every three months. Only urine expected to be free of excreted AMONDYS 45 should be used for monitoring of urine protein. Urine obtained on the day of AMONDYS 45 infusion prior to the infusion, or urine obtained at least 48 hours after the most recent infusion, may be used. Alternatively, use a laboratory test that does not use the reagent pyrogallol red, as this reagent has the potential to cross react with any AMONDYS 45 that is excreted in the urine and thus lead to a false positive result for urine protein.

If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.

Adverse reactions observed in at least 20% of patients treated with AMONDYS 45 and at least 5% more frequently than in the placebo group were (AMONDYS 45, placebo): upper respiratory tract infections (65%, 55%), cough (33%, 26%), pyrexia (33%, 23%), headache (32%, 19%), arthralgia (21%, 10%), and oropharyngeal pain (21%, 7%).

Other adverse reactions that occurred in at least 10% of patients treated with AMONDYS 45 and at least 5% more frequently in the placebo group, were: ear pain, nausea, ear infection, post-traumatic pain, and dizziness and light-headedness.

For further information, please see the full Prescribing Information.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.comor follow us on Twitter, LinkedIn, Instagram and Facebook.

Forward-Looking Statements

In order to provide Sarepta’s investors with an understanding of its current results and future prospects, this press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “may,” “intends,” “prepares,” “looks,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to our future operations, financial performance and projections, business plans, market opportunities, priorities and research and development programs and technologies; the potential benefits of our technologies and scientific approaches; the potential benefits of our product candidates; our upcoming Advisory Committee meeting for SRP-9001 on May 12, including sharing the totality of evidence supporting the safety and efficacy of SRP-9001 at such meeting; the May 29, 2023 regulatory action date for our BLA for SRP-9001; a potential launch of SRP-9001 in the United States; receiving data from Part B of Study 5051-201 in the second half of this year; our anticipation that, if successful, Part B of Study 5051-201 will serve as the pivotal study for SRP-5051 and that we will seek accelerated approval; completing enrollment for VOYAGENE in the second half of 2023; and beginning our phase 3 study using commercially representative process material by the end of this year for SRP-9003.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to comply with all FDA post-approval commitments and requirements with respect to our products in a timely manner or at all; success in preclinical and clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and the results of future research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; certain programs may never advance in the clinic or may be discontinued for a number of reasons, including regulators imposing a clinical hold and us suspending or terminating clinical research or trials; products intended for use in gene therapies are novel, complex and difficult to manufacture and we could experience production problems that result in delays in our development or commercialization of gene therapy programs, limit the supply of our product candidates or future approved products or otherwise harm our business; only a few gene therapy products have been approved in the U.S. and EU and if we are unable to show the safety and efficacy of these product candidates, experience delays in doing so or are unable to successfully commercialize at least one of these drugs, our business would be materially harmed; because we are developing product candidates for the treatment of certain diseases in which there is little clinical experience and we are using new endpoints or methodologies, there is increased risk that the FDA, the EMA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze; if the actual number of patients suffering from the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, some of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, the COVID-19 pandemic and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading “Risk Factors” in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 and our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Internet Posting of Information

We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

 

Sarepta Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(unaudited, in thousands, except per share amounts)

 

 

 

For the Three Months Ended

March 31,

 

 

 

2023

 

 

2022

 

Revenues:

 

 

 

 

 

 

Products, net

 

$

231,495

 

 

$

188,825

 

Collaboration

 

 

22,005

 

 

 

22,005

 

Total revenues

 

 

253,500

 

 

 

210,830

 

Cost and expenses:

 

 

 

 

 

 

Cost of sales (excluding amortization of in-licensed rights)

 

 

35,017

 

 

 

31,443

 

Research and development

 

 

245,679

 

 

 

194,250

 

Selling, general and administrative

 

 

110,714

 

 

 

71,840

 

Amortization of in-licensed rights

 

 

178

 

 

 

178

 

Total cost and expenses

 

 

391,588

 

 

 

297,711

 

Operating loss

 

 

(138,088

)

 

 

(86,881

)

Other loss, net:

 

 

 

 

 

 

Loss on debt extinguishment

 

 

(387,329

)

 

 

 

Other income (expense), net

 

 

12,707

 

 

 

(17,265

)

Total other loss, net

 

 

(374,622

)

 

 

(17,265

)

 

 

 

 

 

 

 

Loss before income tax expense

 

 

(512,710

)

 

 

(104,146

)

Income tax expense

 

 

4,045

 

 

 

879

 

Net loss

 

$

(516,755

)

 

$

(105,025

)

 

 

 

 

 

 

 

Net loss per share — basic and diluted

 

$

(5.86

)

 

$

(1.20

)

 

 

 

 

 

 

 

Weighted average number of shares of common stock used in computing basic and diluted net loss per share

 

 

88,186

 

 

 

87,253

 

 

Sarepta Therapeutics, Inc.

 

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

 

(unaudited, in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

March 31,

 

 

 

2023

 

 

2022

 

 

 

 

 

 

 

 

GAAP net loss

 

$

(516,755

)

 

$

(105,025

)

Interest (income) expense, net

 

 

(12,992

)

 

 

15,581

 

Income tax expense

 

 

4,045

 

 

 

879

 

Impairment of equity investment

 

 

321

 

 

 

 

Loss on debt extinguishment

 

 

387,329

 

 

 

 

Depreciation and amortization expense

 

 

11,305

 

 

 

10,719

 

Stock-based compensation expense

 

 

41,250

 

 

 

29,198

 

Non-GAAP net loss

 

$

(85,497

)

 

$

(48,648

)

 

 

 

 

 

 

 

Non-GAAP net loss per share:

 

 

 

 

 

 

Basic and diluted

 

$

(0.97

)

 

$

(0.56

)

 

 

 

 

 

 

 

Weighted average number of shares of common stock used in computing earnings per share:

 

 

 

 

 

 

Basic and diluted

 

 

88,186

 

 

 

87,253

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

March 31,

 

 

 

2023

 

 

2022

 

GAAP research and development expenses

 

$

245,679

 

 

$

194,250

 

Stock-based compensation expense

 

 

(16,413

)

 

 

(13,068

)

Depreciation and amortization expense

 

 

(8,551

)

 

 

(8,022

)

Non-GAAP research and development expenses

 

$

220,715

 

 

$

173,160

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

March 31,

 

 

 

2023

 

 

2022

 

GAAP selling, general and administrative expenses

 

$

110,714

 

 

$

71,840

 

Stock-based compensation expense

 

 

(24,837

)

 

 

(16,130

)

Depreciation and amortization expense

 

 

(2,576

)

 

 

(2,519

)

Non-GAAP selling, general and administrative expenses

 

$

83,301

 

 

$

53,191

 

 

Sarepta Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(unaudited, in thousands, except share and per share data)

 

 

 

As of

March 31, 2023

 

 

As of

December 31, 2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

871,668

 

 

$

966,777

 

Short-term investments

 

 

1,010,429

 

 

 

1,022,597

 

Accounts receivable

 

 

223,836

 

 

 

214,628

 

Inventory

 

 

202,675

 

 

 

203,968

 

Other current assets

 

 

179,769

 

 

 

149,891

 

Total current assets

 

 

2,488,377

 

 

 

2,557,861

 

Property and equipment, net

 

 

182,862

 

 

 

180,037

 

Right of use assets

 

 

62,016

 

 

 

64,954

 

Non-current inventory

 

 

164,144

 

 

 

162,545

 

Other non-current assets

 

 

162,387

 

 

 

162,969

 

Total assets

 

$

3,059,786

 

 

$

3,128,366

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

106,710

 

 

$

95,875

 

Accrued expenses

 

 

345,554

 

 

 

418,996

 

Deferred revenue, current portion

 

 

67,239

 

 

 

89,244

 

Other current liabilities

 

 

17,381

 

 

 

15,489

 

Total current liabilities

 

 

536,884

 

 

 

619,604

 

Long-term debt

 

 

1,234,284

 

 

 

1,544,292

 

Lease liabilities, net of current portion

 

 

53,931

 

 

 

57,578

 

Deferred revenue, net of current portion

 

 

485,000

 

 

 

485,000

 

Contingent consideration

 

 

36,900

 

 

 

36,900

 

Other non-current liabilities

 

 

38

 

 

 

42

 

Total liabilities

 

 

2,347,037

 

 

 

2,743,416

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding

 

 

 

 

 

 

Common stock, $0.0001 par value, 198,000,000 shares authorized; 93,140,135 and 87,950,117 issued and outstanding at March 31, 2023 and December 31, 2022, respectively

 

 

9

 

 

 

9

 

Additional paid-in capital

 

 

5,140,150

 

 

 

4,296,841

 

Accumulated other comprehensive loss, net of tax

 

 

(419

)

 

 

(1,664

)

Accumulated deficit

 

 

(4,426,991

)

 

 

(3,910,236

)

Total stockholders’ equity

 

 

712,749

 

 

 

384,950

 

Total liabilities and stockholders’ equity

 

$

3,059,786

 

 

$

3,128,366

 

 

Investor Contact:

Ian Estepan, 617-274-4052

[email protected]

Media Contact:

Tracy Sorrentino, 617-301-8566

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Science Other Science Biotechnology Research Pharmaceutical Health Genetics Other Health

MEDIA:

Logo
Logo

Paycom Software, Inc. Reports First Quarter 2023 Results

Paycom Software, Inc. Reports First Quarter 2023 Results

First Quarter Revenues of $452 million, up 28% from the comparable prior year period

First Quarter GAAP Net Income of $119 million, representing 26% of total revenues, or $2.06 per diluted share

First Quarter Non-GAAP Net Income of $143 million, of $2.46 per diluted share

First Quarter Adjusted EBITDA of $221 million, representing 49% of total revenues

OKLAHOMA CITY–(BUSINESS WIRE)–
Paycom Software, Inc. (“Paycom,” “we” and “our”) (NYSE: PAYC), a leading provider of comprehensive, cloud-based human capital management software, today announced its financial results for the quarter ended March 31, 2023.

“Results for the first quarter of 2023 were excellent, with robust revenue growth from new clients and expanding margins, as demand for automation and our easy-to-use HCM solutions continues to increase,” said Paycom’s founder, chairman and CEO, Chad Richison. “Our unique value proposition, particularly with Beti where employees do their own payroll, continues to resonate with clients and their employees.”

Financial Highlights for the First Quarter of 2023

Total Revenues of $451.6 million represented a 27.8% increase compared to total revenues of $353.5 million in the same period last year. Recurring revenues of $444.4 million increased 27.6% from the comparable prior year period, and constituted 98.4% of total revenues.

GAAP Net Income was $119.3 million, or $2.06 per diluted share, compared to GAAP net income of $91.9 million, or $1.58 per diluted share, in the same period last year.

Non-GAAP Net Income1was $142.7 million, or $2.46 per diluted share, compared to $110.6 million, or $1.90 per diluted share, in the same period last year.

Adjusted EBITDA1 was $220.5 million, compared to $170.1 million in the same period last year.

Cash and Cash Equivalents were $505.6 million as of March 31, 2023, compared to $400.7 million as of December 31, 2022.

Total Debt was $29.0 million as of March 31, 2023 and December 31, 2022.

1 Adjusted EBITDA and non-GAAP net income are non-GAAP financial measures. Please see the discussion below under the heading “Use of Non-GAAP Financial Information” and the reconciliations at the end of this release for additional information concerning these and other non-GAAP financial measures.

Financial Outlook

Paycom provides the following expected financial guidance for the quarter ending June 30, 2023 and the year ending December 31, 2023.

Quarter Ending June 30, 2023:

Total Revenues in the range of $397 million to $399 million.

Adjusted EBITDA in the range of $152 million to $154 million.

Year Ending December 31, 2023:

Total Revenues in the range of $1.713 billion to $1.715 billion.

Adjusted EBITDA in the range of $717 million to $719 million.

We have not reconciled the forward-looking adjusted EBITDA ranges presented above and discussed on the teleconference call to net income, nor the forward-looking adjusted EBITDA margins and forward looking non-GAAP effective income tax rate discussed on the teleconference call to comparable GAAP measures, because applicable information for future periods, on which these reconciliations would be based, is not readily available due to uncertainty regarding, and the potential variability of, depreciation and amortization, interest expense, taxes, non-cash stock-based compensation expense and other items. Further, we have not reconciled the forward-looking adjusted gross margin discussed on the teleconference call to GAAP gross margin because applicable information for future periods, on which this reconciliation would be based, is not readily available due to uncertainty regarding, and the potential variability of, cost of revenues, including non-cash stock-based compensation expense. Accordingly, reconciliations of the forward-looking adjusted EBITDA ranges to net income, the forward-looking adjusted EBITDA margins to net income margin, the forward-looking adjusted gross margin to gross margin, and the forward-looking non-GAAP effective income tax rate to the GAAP effective income tax rate are not available at this time without unreasonable effort. During the teleconference call, we also refer to a forward-looking estimate of our implied revenue growth rate plus adjusted EBITDA margin, or the “Rule of 65”. Because we are unable to reconcile forward-looking adjusted EBITDA margin to net income margin without unreasonable effort, we are unable to reconcile the “Rule of 65” to a comparable GAAP measure without unreasonable effort.

Use of Non-GAAP Financial Information

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this press release and on the related teleconference call, including adjusted EBITDA, non-GAAP net income, adjusted gross profit, adjusted gross margin, adjusted sales and marketing expenses, adjusted total administrative expenses, adjusted research and development expenses, adjusted total research and development costs, adjusted EBITDA margin, and “Rule of 65”. Management uses these non-GAAP financial measures as supplemental measures to review and assess the performance of our core business operations and for planning purposes. We define (i) adjusted EBITDA as net income plus interest expense, taxes, depreciation and amortization, non-cash stock-based compensation expense, certain transaction expenses that are not core to our operations (if any) and the change in fair value of our interest rate swap, (ii) non-GAAP net income as net income plus non-cash stock-based compensation expense, certain transaction expenses that are not core to our operations (if any) and the change in fair value of our interest rate swap, all of which are adjusted for the effect of income taxes, (iii) adjusted gross profit as gross profit plus applicable non-cash stock-based compensation expense, (iv) adjusted gross margin as gross profit plus applicable non-cash stock-based compensation expense, divided by total revenues, (v) each adjusted expense item as the GAAP expense amount less applicable non-cash stock-based compensation expense, (vi) adjusted total research and development costs as total research and development costs (including the capitalized portion) less applicable non-cash stock-based compensation (including the capitalized portion), (vii) adjusted EBITDA margin as adjusted EBITDA (calculated as described in clause (i)) divided by total revenues, and (viii) “Rule of 65” as revenue growth rate (expressed as a percentage) plus adjusted EBITDA margin (calculated as described in clause (vii)) and (ix) non-GAAP effective income tax rate as the provision for income taxes plus the income tax effect on non-GAAP adjustments divided by non-GAAP net income (calculated as described in clause (ii)) plus the provision for income taxes and the income tax effect on non-GAAP adjustments. The non-GAAP financial measures presented in this press release and discussed on the related teleconference call provide investors with greater transparency to the information used by management in its financial and operational decision-making. We believe these metrics are useful to investors because they facilitate comparisons of our core business operations across periods on a consistent basis, as well as comparisons with the results of peer companies, many of which use similar non-GAAP financial measures to supplement results under GAAP. In addition, adjusted EBITDA is a measure that provides useful information to management about the amount of cash available for reinvestment in our business, repurchasing common stock and other purposes. Management believes that the non-GAAP measures presented in this press release and discussed on the related teleconference call, when viewed in combination with our results prepared in accordance with GAAP, provide a more complete understanding of the factors and trends affecting our business and performance.

The non-GAAP financial measures presented in this press release and discussed on the related teleconference call are not measures of financial performance under GAAP and should not be considered a substitute for net income, gross profit, gross margin, research and development expenses, sales and marketing expenses, administrative expenses and total research and development costs. Non-GAAP financial measures have limitations as analytical tools, and when assessing our operating performance, you should not consider these non-GAAP financial measures in isolation, or as a substitute for the consolidated statements of income data prepared in accordance with GAAP. The non-GAAP financial measures that we present may not be comparable to similarly titled measures of other companies and other companies may not calculate such measures in the same manner as we do.

Conference Call Details:

In conjunction with this announcement, Paycom will host a conference call today, May 2, 2023, at 5:00 p.m. Eastern time to discuss its financial results. To access this call, dial (833) 470-1428 (domestic) or (404) 975-4839 (international) and provide 863310 as the access code. A live webcast as well as the replay of the conference call will be available on the Investor Relations page of Paycom’s website at investors.paycom.com.

About Paycom

For nearly 25 years, Paycom Software, Inc. (NYSE:PAYC) has simplified businesses and the lives of their employees through easy-to-use HR and payroll technology to empower transparency through direct access to their data. And thanks to its industry-first solution, Beti®, U.S. employees now do their own payroll and are guided to find and fix costly errors before payroll submission. From onboarding and benefits enrollment to talent management and more, Paycom’s software streamlines processes, drives efficiencies and gives employees power over their own HR information, all in a single app. Recognized nationally for its technology and workplace culture, Paycom can now serve businesses of all sizes in the U.S. and internationally.

Forward-Looking Statements

Certain statements in this press release are, and certain statements on the related teleconference call may be, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that refer to Paycom’s estimated or anticipated results, other non-historical facts or future events and include, but are not limited to, statements regarding our business strategy; anticipated future operating results and operating expenses, cash flows, capital resources, dividends and liquidity; trends, opportunities and risks affecting our business, industry and financial results; future expansion or growth plans and potential for future growth; our ability to attract new clients to purchase our solution; our ability to retain clients and induce them to purchase additional applications; our ability to accurately forecast future revenues and appropriately plan our expenses; market acceptance of our solution and applications; our expectations regarding future revenues generated by certain applications; our ability to attract and retain qualified employees and key personnel; future regulatory, judicial and legislative changes; how certain factors affecting our performance correlate to improvement or deterioration in the labor market; our plan to open additional sales offices and our ability to effectively execute such plan; the sufficiency of our existing cash and cash equivalents to meet our working capital and capital expenditure needs over the next 12 months; our plans regarding our capital expenditures and investment activity as our business grows, including with respect to research and development and the expansion of our corporate headquarters and other facilities; our plans to pay cash dividends; our plans to repurchase shares of our common stock through a stock repurchase plan; and our expected income tax rate for future periods. In addition, forward-looking statements also consist of statements involving trend analyses and statements including such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “will,” “would,” and similar expressions or the negative of such terms or other comparable terminology. These forward-looking statements speak only as of the date hereof and are subject to business and economic risks. As such, our actual results could differ materially from those set forth in the forward-looking statements as a result of the factors discussed in our filings with the Securities and Exchange Commission, including but not limited to those discussed in our most recent Annual Report on Form 10-K. We do not undertake any obligation to update or revise the forward-looking statements to reflect events or circumstances that exist after the date on which such statements were made, except to the extent required by law.

Paycom Software, Inc.

 

Unaudited Consolidated Balance Sheets

 

(in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

March 31, 2023

 

 

December 31, 2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

505,590

 

 

$

400,730

 

Accounts receivable

 

 

17,802

 

 

 

22,843

 

Prepaid expenses

 

 

40,260

 

 

 

34,056

 

Inventory

 

 

887

 

 

 

1,607

 

Income tax receivable

 

 

 

 

 

5,583

 

Deferred contract costs

 

 

102,374

 

 

 

96,378

 

Current assets before funds held for clients

 

 

666,913

 

 

 

561,197

 

Funds held for clients

 

 

2,387,778

 

 

 

2,202,975

 

Total current assets

 

 

3,054,691

 

 

 

2,764,172

 

Property and equipment, net

 

 

421,017

 

 

 

402,448

 

Intangible assets, net

 

 

53,040

 

 

 

54,017

 

Goodwill

 

 

51,889

 

 

 

51,889

 

Long-term deferred contract costs

 

 

602,205

 

 

 

567,974

 

Other assets

 

 

58,780

 

 

 

62,013

 

Total assets

 

$

4,241,622

 

 

$

3,902,513

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

10,036

 

 

$

16,054

 

Income tax payable

 

 

19,350

 

 

 

 

Accrued commissions and bonuses

 

 

17,594

 

 

 

28,439

 

Accrued payroll and vacation

 

 

36,188

 

 

 

45,023

 

Deferred revenue

 

 

20,505

 

 

 

19,825

 

Accrued expenses and other current liabilities

 

 

70,090

 

 

 

59,990

 

Current liabilities before client funds obligation

 

 

173,763

 

 

 

169,331

 

Client funds obligation

 

 

2,391,335

 

 

 

2,207,706

 

Total current liabilities

 

 

2,565,098

 

 

 

2,377,037

 

Deferred income tax liabilities, net

 

 

139,661

 

 

 

141,033

 

Long-term deferred revenue

 

 

100,297

 

 

 

97,591

 

Long-term debt

 

 

29,000

 

 

 

29,000

 

Other long-term liabilities

 

 

73,095

 

 

 

75,245

 

Total long-term liabilities

 

 

342,053

 

 

 

342,869

 

Total liabilities

 

 

2,907,151

 

 

 

2,719,906

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.01 par value (100,000 shares authorized, 62,525 and 62,518 shares issued at March 31, 2023 and December 31, 2022, respectively; 57,872 and 57,867 shares outstanding at March 31, 2023 and December 31, 2022, respectively)

 

 

625

 

 

 

625

 

Additional paid-in capital

 

 

608,966

 

 

 

576,622

 

Retained earnings

 

 

1,316,264

 

 

 

1,196,968

 

Accumulated other comprehensive earnings (loss)

 

 

(2,853

)

 

 

(3,703

)

Treasury stock, at cost (4,653 and 4,651 shares at March 31, 2023 and December 31, 2022, respectively)

 

 

(588,531

)

 

 

(587,905

)

Total stockholders’ equity

 

 

1,334,471

 

 

 

1,182,607

 

Total liabilities and stockholders’ equity

 

$

4,241,622

 

 

$

3,902,513

 

 

Paycom Software, Inc.

 

Unaudited Consolidated Statements of Comprehensive Income

 

(in thousands, except per share amounts)

 

 

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Revenues

 

 

 

 

 

 

Recurring

 

$

444,421

 

 

$

348,164

 

Implementation and other

 

 

7,216

 

 

 

5,355

 

Total revenues

 

 

451,637

 

 

 

353,519

 

Cost of revenues

 

 

 

 

 

 

Operating expenses

 

 

53,085

 

 

 

38,492

 

Depreciation and amortization

 

 

12,147

 

 

 

9,992

 

Total cost of revenues

 

 

65,232

 

 

 

48,484

 

Administrative expenses

 

 

 

 

 

 

Sales and marketing

 

 

103,574

 

 

 

74,996

 

Research and development

 

 

42,669

 

 

 

31,605

 

General and administrative

 

 

65,605

 

 

 

60,504

 

Depreciation and amortization

 

 

14,125

 

 

 

11,663

 

Total administrative expenses

 

 

225,973

 

 

 

178,768

 

Total operating expenses

 

 

291,205

 

 

 

227,252

 

Operating income

 

 

160,432

 

 

 

126,267

 

Interest expense

 

 

(837

)

 

 

(215

)

Other income (expense), net

 

 

6,004

 

 

 

1,412

 

Income before income taxes

 

 

165,599

 

 

 

127,464

 

Provision for income taxes

 

 

46,303

 

 

 

35,534

 

Net income

 

$

119,296

 

 

$

91,930

 

Earnings per share, basic

 

$

2.06

 

 

$

1.58

 

Earnings per share, diluted

 

$

2.06

 

 

$

1.58

 

Weighted average shares outstanding:

 

 

 

 

 

 

Basic

 

 

57,867

 

 

 

58,014

 

Diluted

 

 

57,991

 

 

 

58,219

 

Comprehensive earnings (loss):

 

 

 

 

 

 

Net income

 

$

119,296

 

 

$

91,930

 

Unrealized net gains (losses) on available-for-sale securities

 

 

1,050

 

 

 

(1,522

)

Tax effect

 

 

(200

)

 

 

403

 

Other comprehensive income (loss), net of tax

 

 

850

 

 

 

(1,119

)

Comprehensive earnings (loss)

 

$

120,146

 

 

$

90,811

 

 

Paycom Software, Inc.

 

Unaudited Consolidated Statements of Cash Flows

 

(in thousands)

 

 

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Cash flows from operating activities

 

 

 

 

 

 

Net income

 

$

119,296

 

 

$

91,930

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

26,272

 

 

 

21,655

 

Accretion of discount on available-for-sale securities

 

 

(124

)

 

 

(303

)

Non-cash marketing expense

 

 

418

 

 

 

437

 

Gain on disposition of property and equipment

 

 

(13

)

 

 

 

Amortization of debt issuance costs

 

 

308

 

 

 

9

 

Stock-based compensation expense

 

 

27,819

 

 

 

22,055

 

Cash paid for derivative settlement

 

 

 

 

 

(174

)

Gain on derivative

 

 

 

 

 

(1,089

)

Deferred income taxes, net

 

 

(1,650

)

 

 

(10,332

)

Other

 

 

78

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

5,041

 

 

 

(8,455

)

Prepaid expenses

 

 

(6,984

)

 

 

(4,859

)

Inventory

 

 

385

 

 

 

124

 

Other assets

 

 

2,923

 

 

 

(2,970

)

Deferred contract costs

 

 

(38,519

)

 

 

(36,261

)

Accounts payable

 

 

(4,645

)

 

 

5,406

 

Income taxes, net

 

 

24,933

 

 

 

39,593

 

Accrued commissions and bonuses

 

 

(10,845

)

 

 

(10,309

)

Accrued payroll and vacation

 

 

(8,835

)

 

 

8,579

 

Deferred revenue

 

 

3,386

 

 

 

3,390

 

Accrued expenses and other current liabilities

 

 

6,859

 

 

 

(1,195

)

Net cash provided by operating activities

 

 

146,103

 

 

 

117,231

 

Cash flows from investing activities

 

 

 

 

 

 

Purchases of investments from funds held for clients

 

 

(25,000

)

 

 

(169,152

)

Proceeds from investments from funds held for clients

 

 

25,000

 

 

 

136,000

 

Purchases of property and equipment

 

 

(40,618

)

 

 

(34,474

)

Net cash used in investing activities

 

 

(40,618

)

 

 

(67,626

)

Cash flows from financing activities

 

 

 

 

 

 

Withholding taxes paid related to net share settlements

 

 

(626

)

 

 

(218

)

Payments on long-term debt

 

 

 

 

 

(444

)

Net change in client funds obligation

 

 

183,629

 

 

 

2,099,530

 

Net cash provided by financing activities

 

 

183,003

 

 

 

2,098,868

 

Increase in cash, cash equivalents, restricted cash and restricted cash equivalents

 

 

288,488

 

 

 

2,148,473

 

Cash, cash equivalents, restricted cash and restricted cash equivalents

 

 

 

 

 

 

Cash, cash equivalents, restricted cash and restricted cash equivalents, beginning of period

 

 

2,409,095

 

 

 

1,812,691

 

Cash, cash equivalents, restricted cash and restricted cash equivalents, end of period

 

$

2,697,583

 

 

$

3,961,164

 

 

Paycom Software, Inc.

 

Unaudited Consolidated Statements of Cash Flows

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Reconciliation of cash, cash equivalents, restricted cash and restricted cash equivalents

 

 

 

 

 

 

Cash and cash equivalents

 

$

505,590

 

 

$

360,594

 

Restricted cash included in funds held for clients

 

 

2,191,993

 

 

 

3,600,570

 

Total cash, cash equivalents, restricted cash and restricted cash equivalents, end of period

 

$

2,697,583

 

 

$

3,961,164

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

 

Purchases of property and equipment, accrued but not paid

 

$

6,991

 

 

$

5,394

 

Stock-based compensation for capitalized software

 

$

3,597

 

 

$

1,891

 

Right of use assets obtained in exchange for operating lease liabilities

 

$

1,933

 

 

$

4,146

 

 

Paycom Software, Inc.

Unaudited Reconciliations of GAAP to Non-GAAP Financial Measures

(in thousands, except per share amounts)

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Net income to adjusted EBITDA:

 

 

 

 

 

 

Net income

 

$

119,296

 

 

$

91,930

 

Interest expense

 

 

837

 

 

 

215

 

Provision for income taxes

 

 

46,303

 

 

 

35,534

 

Depreciation and amortization

 

 

26,272

 

 

 

21,655

 

EBITDA

 

 

192,708

 

 

 

149,334

 

Non-cash stock-based compensation expense

 

 

27,819

 

 

 

22,055

 

Change in fair value of interest rate swap

 

 

 

 

 

(1,263

)

Adjusted EBITDA

 

$

220,527

 

 

$

170,126

 

Net income margin

 

 

26.4

%

 

 

26.0

%

Adjusted EBITDA margin

 

 

48.8

%

 

 

48.1

%

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Net income to non-GAAP net income:

 

 

 

 

 

 

Net income

 

$

119,296

 

 

$

91,930

 

Non-cash stock-based compensation expense

 

 

27,819

 

 

 

22,055

 

Change in fair value of interest rate swap

 

 

 

 

 

(1,263

)

Income tax effect on non-GAAP adjustments

 

 

(4,464

)

 

 

(2,074

)

Non-GAAP net income

 

$

142,651

 

 

$

110,648

 

 

 

 

 

 

 

 

Weighted average shares outstanding:

 

 

 

 

 

 

Basic

 

 

57,867

 

 

 

58,014

 

Diluted

 

 

57,991

 

 

 

58,219

 

 

 

 

 

 

 

 

Earnings per share, basic

 

$

2.06

 

 

$

1.58

 

Earnings per share, diluted

 

$

2.06

 

 

$

1.58

 

Non-GAAP net income per share, basic

 

$

2.47

 

 

$

1.91

 

Non-GAAP net income per share, diluted

$

2.46

$

1.90

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Earnings per share to non-GAAP net income per share, basic:

 

 

 

 

 

 

Earnings per share, basic

 

$

2.06

 

 

$

1.58

 

Non-cash stock-based compensation expense

 

 

0.48

 

 

 

0.38

 

Change in fair value of interest rate swap

 

 

 

 

 

(0.02

)

Income tax effect on non-GAAP adjustments

 

 

(0.07

)

 

 

(0.03

)

Non-GAAP net income per share, basic

 

$

2.47

 

 

$

1.91

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Earnings per share to non-GAAP net income per share, diluted:

 

 

 

 

 

 

Earnings per share, diluted

 

$

2.06

 

 

$

1.58

 

Non-cash stock-based compensation expense

 

 

0.48

 

 

 

0.38

 

Change in fair value of interest rate swap

 

 

 

 

 

(0.02

)

Income tax effect on non-GAAP adjustments

 

 

(0.08

)

 

 

(0.04

)

Non-GAAP net income per share, diluted

 

$

2.46

 

 

$

1.90

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Adjusted gross profit:

 

 

 

 

 

 

Total revenues

 

$

451,637

 

 

$

353,519

 

Less: Total cost of revenues

 

 

(65,232

)

 

 

(48,484

)

Total gross profit

 

 

386,405

 

 

 

305,035

 

Plus: Non-cash stock-based compensation expense

 

 

2,385

 

 

 

982

 

Total adjusted gross profit

 

$

388,790

 

 

$

306,017

 

Gross margin

 

 

85.6

%

 

 

86.3

%

Adjusted gross margin

 

 

86.1

%

 

 

86.6

%

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Adjusted sales and marketing expenses:

 

 

 

 

 

 

Sales and marketing expenses

 

$

103,574

 

 

$

74,996

 

Less: Non-cash stock-based compensation expense

 

 

(5,476

)

 

 

(2,877

)

Adjusted sales and marketing expenses

 

$

98,098

 

 

$

72,119

 

 

 

 

 

 

 

 

Total revenues

 

$

451,637

 

 

$

353,519

 

Sales and marketing expenses as a % of revenues

 

 

22.9

%

 

 

21.2

%

Adjusted sales and marketing expenses as a % of revenues

 

 

21.7

%

 

 

20.4

%

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Adjusted total administrative expenses:

 

 

 

 

 

 

Total administrative expenses

 

$

225,973

 

 

$

178,768

 

Less: Non-cash stock-based compensation expense

 

 

(25,434

)

 

 

(21,073

)

Adjusted total administrative expenses

 

$

200,539

 

 

$

157,695

 

 

 

 

 

 

 

 

Total revenues

 

$

451,637

 

 

$

353,519

 

Total administrative expenses as a % of revenues

 

 

50.0

%

 

 

50.5

%

Adjusted total administrative expenses as a % of revenues

 

 

44.4

%

 

 

44.6

%

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Adjusted research and development expenses:

 

 

 

 

 

 

Research and development expenses

 

$

42,669

 

 

$

31,605

 

Less: Non-cash stock-based compensation expense

 

 

(5,258

)

 

 

(2,219

)

Adjusted research and development expenses

 

$

37,411

 

 

$

29,386

 

 

 

 

 

 

 

 

Total revenues

 

$

451,637

 

 

$

353,519

 

Research and development expenses as a % of revenues

 

 

9.4

%

 

 

8.9

%

Adjusted research and development expenses as a % of revenues

 

 

8.3

%

 

 

8.3

%

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Total research and development costs:

 

 

 

 

 

 

Capitalized research and development costs

 

$

21,353

 

 

$

15,400

 

Research and development expenses

 

 

42,669

 

 

 

31,605

 

Total research and development costs

 

$

64,022

 

 

$

47,005

 

 

 

 

 

 

 

 

Total revenues

 

$

451,637

 

 

$

353,519

 

Total research and development costs as a % of revenues

 

 

14.2

%

 

 

13.3

%

 

 

 

 

 

 

 

Adjusted total research and development costs:

 

 

 

 

 

 

Total research and development costs

 

$

64,022

 

 

$

47,005

 

Less: Capitalized non-cash stock-based compensation

 

 

(3,597

)

 

 

(1,891

)

Less: Non-cash stock-based compensation expense

 

 

(5,258

)

 

 

(2,219

)

Adjusted total research and development costs

 

$

55,167

 

 

$

42,895

 

 

 

 

 

 

 

 

Total revenues

 

$

451,637

 

 

$

353,519

 

Adjusted total research and development costs as a % of revenues

 

 

12.2

%

 

 

12.1

%

Paycom Software, Inc.

Unaudited Components of Non-Cash Stock-Based Compensation Expense

(in thousands)

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Non-cash stock-based compensation expense:

 

 

 

 

 

 

Operating expenses

 

$

2,385

 

 

$

982

 

Sales and marketing

 

 

5,476

 

 

 

2,877

 

Research and development

 

 

5,258

 

 

 

2,219

 

General and administrative

 

 

14,700

 

 

 

15,977

 

Total non-cash stock-based compensation expense

 

$

27,819

 

 

$

22,055

 

 

Paycom Software, Inc.

Investor Relations:

James Samford, 800-580-4505

[email protected]

KEYWORDS: Oklahoma United States North America

INDUSTRY KEYWORDS: Payments Professional Services Technology Software Human Resources

MEDIA:

Logo
Logo

James River Announces First Quarter 2023 Results

PEMBROKE, Bermuda, May 02, 2023 (GLOBE NEWSWIRE) — James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR) today reported first quarter 2023 net income available to common shareholders of $7.0 million ($0.18 per diluted share), compared to net income available to common shareholders of $9.3 million ($0.25 per diluted share) for the first quarter of 2022. Adjusted net operating income1 for the first quarter of 2023 was $21.6 million ($0.56 per diluted share), compared to adjusted net operating income1 of $13.9 million ($0.37 per diluted share) for the first quarter of 2022.

First Quarter 2023 Highlights:

  • Group combined ratio of 94.9% and Excess and Surplus Lines (“E&S”) segment combined ratio of 86.8% on business not subject to retroactive reinsurance accounting for loss portfolio transfers (the “combined ratio”). Unless specified otherwise, all underwriting performance ratios presented herein are for our business not subject to retroactive reinsurance accounting for loss portfolio transfers (“LPTs”).
  • E&S segment gross and net written premium growth of 12.1% and 17.3%, respectively, due to strong growth from our larger underwriting divisions, broad based renewal rate increases and increased net retention.
  • E&S segment renewal rates increased 8.9%, with all underwriting divisions reporting positive pricing increases.
  • Net investment income increased 58.4% compared to the prior year quarter, and 12.9% sequentially due to higher income from most asset classes.
  • Adjusted net operating return on tangible common equity excluding accumulated other comprehensive loss (“AOCI”)1 of 16.3%.

Frank D’Orazio, the Company’s Chief Executive Officer, commented on the first quarter, “Buoyed by strong growth and attractive renewal rates in our E&S segment, solid underwriting profitability and meaningful contributions from our investment portfolio, James River produced another outstanding quarter of attractive returns, including our strongest quarterly adjusted net operating income in more than three years. With the Company repositioned around its core strengths, we believe James River is well poised to continue to deliver excellent underwriting performance and compelling shareholder returns.”

______________________
1 Adjusted net operating income and adjusted net operating return on tangible common equity excluding AOCI are non-GAAP financial measures. See “Non-GAAP Financial Measures” and “Reconciliation of Non-GAAP Financial Measures” at the end of this press release.

First Quarter 2023 Operating Results

  • Gross written premium of $363.9 million, consisting of the following:
  Three Months Ended

March 31,
 

($ in thousands)
  2023     2022  
% Change
Excess and Surplus Lines $ 228,903   $ 204,282   12 %
Specialty Admitted Insurance   124,551     125,710   (1 )%
Casualty Reinsurance   10,439     29,944   (65 )%
  $ 363,893   $ 359,936   1 %
                 
  • Net written premium of $183.2 million, consisting of the following:
  Three Months Ended

March 31,
 

($ in thousands)
  2023     2022  
% Change
Excess and Surplus Lines $ 147,430   $ 125,710   17 %
Specialty Admitted Insurance   26,725     20,205   32 %
Casualty Reinsurance   9,065     29,944   (70 )%
  $ 183,220   $ 175,859   4 %
                 
  • Net earned premium of $208.1 million, consisting of the following:
  Three Months Ended

March 31,
 

($ in thousands)
  2023     2022  
% Change
Excess and Surplus Lines $ 151,359   $ 131,301   15 %
Specialty Admitted Insurance   20,481     19,318   6 %
Casualty Reinsurance   36,273     39,205   (7)
%
  $ 208,113   $ 189,824   10 %
                 
  • E&S segment gross written premium increased 12.1% compared to the prior year quarter, while net written premium increased 17.3% due to both strong growth and higher net retention within our excess casualty unit. Premium growth for the segment was led by our larger underwriting divisions, with particular strength in excess casualty, excess property and manufacturers and contractors. Renewal rate increases were 8.9% during the first quarter of 2023, representing the twenty-fifth consecutive quarter of renewal rate increases compounding to 67.7%.
  • Gross written premium for the Specialty Admitted Insurance segment decreased 0.9% from the prior year quarter. During the quarter there was a combined 7.1% reduction to premium from our individual risk workers’ compensation business and our large workers’ compensation fronted program, which was partially offset by growth in our remaining fronting and program business.
  • Gross written premium in the Casualty Reinsurance segment totaled $10.4 million and was related to premium adjustments on in-force treaties. As was previously disclosed, we have suspended underwriting business in our Casualty Reinsurance segment and there were no treaties written or renewed during the first quarter. The earning pattern of the business can extend over multiple years and declines in net earned premium for this segment will lag written premium. We expect to continue to report earned premium over the next several quarters.
  • Pre-tax favorable (unfavorable) reserve development by segment on business not subject to retroactive reinsurance accounting for loss portfolio transfers was as follows:
  Three Months Ended

March 31,

($ in thousands)
  2023       2022  
Excess and Surplus Lines $ 324     $ 59  
Specialty Admitted Insurance   171       (63 )
Casualty Reinsurance   (1,857 )     (6,800 )
  $ (1,362 )   $ (6,804 )
               
  • During the first quarter of 2023, for business not subject to LPTs, the Company reported modest favorable reserve development in E&S and Specialty Admitted, and $1.9 million of adverse development in Casualty Reinsurance.
  • The Company recognized adverse prior year development of $41.0 million on the reserves subject to the Commercial Auto LPT, which provides unlimited coverage, and $7.8 million on the reserves subject to the Casualty Reinsurance LPT. Retroactive benefits of $32.0 million were recorded in loss and loss adjustment expenses and the deferred retroactive reinsurance gain on the Balance Sheet is $37.0 million.
  • Gross fee income was as follows:
  Three Months Ended

March 31,
 

($ in thousands)
  2023     2022  
% Change
Specialty Admitted Insurance $ 5,711   $ 5,558   3 %
                 
  • The consolidated expense ratio was 28.4% for the first quarter of 2023, which was an increase from 26.0% in the prior year first quarter. The expense ratio was primarily impacted by changes in reinsurance cessions in both E&S and Specialty Admitted segments that resulted in a lower level of ceding commissions in the current period.

Investment Results

Net investment income for the first quarter of 2023 was $25.8 million, an increase of 58.4% compared to $16.3 million for the same period in 2022. Growth in income was broad-based across the portfolio, driven by higher yields and growth from positive operating cash flow. During the first quarter of 2023, the Company received $1.2 million of additional proceeds from a renewable energy investment that was sold during the fourth quarter of 2022. This payment was reflected in investment income.

The Company’s net investment income consisted of the following:

  Three Months Ended

March 31,
 

($ in thousands)
  2023     2022  
% Change
Renewable Energy Investments $ 1,255   $ 2,682   (53 )%
Other Private Investments   336     217   55 %
All Other Net Investment Income   24,181     13,368   81 %
Total Net Investment Income $ 25,772   $ 16,267   58 %

The Company’s annualized gross investment yield on average fixed maturity, bank loan and equity securities for the three months ended March 31, 2023 was 4.2% (versus 3.0% for the three months ended March 31, 2022). The investment yield increased primarily as a result of higher market yields on fixed maturity securities and bank loans.

Net realized and unrealized gains on investments of $0.4 million for the three months ended March 31, 2023 compared to net realized and unrealized losses on investments of $5.0 million in the prior year quarter. The majority of the realized and unrealized gains during the first quarter of 2023 were related to changes in fair values of our secured bank loan portfolio, partially offset by a decline in the fair value of preferred and common equity securities.

Taxes

The Company’s effective tax rate fluctuates from period to period based on the relative mix of income reported by country and the respective tax rates imposed by each tax jurisdiction. The effective tax rate for the three months ended March 31, 2023 was 24.6%.

Tangible Equity

Tangible equity2 of $555.4 million at March 31, 2023 increased 10.8% compared to tangible equity of $501.2 million at December 31, 2022, due to strong earnings and a decrease in unrealized losses in the Company’s fixed maturity portfolio. AOCI improved by $30.9 million during the first quarter of 2023, due to an increase in the value of the Company’s fixed maturity securities.

Tangible equity excluding AOCI was $687.5 million at March 31, 2023 compared to $664.3 million at December 31, 2022, with the increase primarily driven by positive net income available to common shareholders during the first quarter of 2023.

Capital Management

The Company announced that its Board of Directors declared a cash dividend of $0.05 per common share. This dividend is payable on Friday, June 30, 2023 to all shareholders of record on Monday, June 12, 2023.

______________________
2 Tangible equity is a non-GAAP financial measure. See “Non-GAAP Financial Measures” and “Reconciliation of Non-GAAP Financial Measures” at the end of this press release.

Conference Call

James River will hold a conference call to discuss its first quarter results tomorrow, May 3, 2023 at 9:00 a.m. Eastern Time. Investors may access the conference call by dialing (800) 715-9871, Conference ID 3174764, or via the internet by visiting www.jrvrgroup.com and clicking on the “Investor Relations” link. A webcast replay of the call will be available by visiting the company website.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. In some cases, such forward-looking statements may be identified by terms such as believe, expect, seek, may, will, should, intend, project, anticipate, plan, estimate, guidance or similar words. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Although it is not possible to identify all of these risks and uncertainties, they include, among others, the following: the inherent uncertainty of estimating reserves and the possibility that incurred losses may be greater than our loss and loss adjustment expense reserves; inaccurate estimates and judgments in our risk management may expose us to greater risks than intended; downgrades in the financial strength rating of our regulated insurance subsidiaries impacting our ability to attract and retain insurance and reinsurance business that our subsidiaries write, our competitive position, and our financial condition; the potential loss of key members of our management team or key employees and our ability to attract and retain personnel; adverse economic factors resulting in the sale of fewer policies than expected or an increase in the frequency or severity of claims, or both; the impact of a persistent high inflationary environment on our reserves, the values of our investments and investment returns, and our compensation expenses; exposure to credit risk, interest rate risk and other market risk in our investment portfolio; reliance on a select group of brokers and agents for a significant portion of our business and the impact of our potential failure to maintain such relationships; reliance on a select group of customers for a significant portion of our business and the impact of our potential failure to maintain, or decision to terminate, such relationships; our ability to obtain reinsurance coverage at prices and on terms that allow us to transfer risk, adequately protect our company against financial loss and that supports our growth plans; losses resulting from reinsurance counterparties failing to pay us on reinsurance claims, insurance companies with whom we have a fronting arrangement failing to pay us for claims, or a former customer with whom we have an indemnification arrangement failing to perform its reimbursement obligations, and our potential inability to demand or maintain adequate collateral to mitigate such risks; inadequacy of premiums we charge to compensate us for our losses incurred; changes in laws or government regulation, including tax or insurance law and regulations; changes in U.S. tax laws and the interpretation of certain provisions of Public Law No. 115-97, informally titled the 2017 Tax Cuts and Jobs Act (including associated regulations), which may be retroactive and could have a significant effect on us including, among other things, by potentially increasing our tax rate, as well as on our shareholders; in the event we do not qualify for the insurance company exception to the passive foreign investment company (“PFIC”) rules and are therefore considered a PFIC, there could be material adverse tax consequences to an investor that is subject to U.S. federal income taxation; the Company or any of its foreign subsidiaries becoming subject to U.S. federal income taxation; a failure of any of the loss limitations or exclusions we utilize to shield us from unanticipated financial losses or legal exposures, or other liabilities; losses from catastrophic events, such as natural disasters and terrorist acts, which substantially exceed our expectations and/or exceed the amount of reinsurance we have purchased to protect us from such events; the effects of the COVID-19 pandemic and associated government actions on our operations and financial performance; potential effects on our business of emerging claim and coverage issues; the potential impact of internal or external fraud, operational errors, systems malfunctions or cyber security incidents; our ability to manage our growth effectively; failure to maintain effective internal controls in accordance with the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley”); changes in our financial condition, regulations or other factors that may restrict our subsidiaries’ ability to pay us dividends; and an adverse result in any litigation or legal proceedings we are or may become subject to. Additional information about these risks and uncertainties, as well as others that may cause actual results to differ materially from those in the forward-looking statements, is contained in our filings with the U.S. Securities and Exchange Commission (“SEC”), including our most recently filed Annual Report on Form 10-K. These forward-looking statements speak only as of the date of this release and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

Non-GAAP Financial Measures

In presenting James River Group Holdings, Ltd.’s results, management has included financial measures that are not calculated under standards or rules that comprise accounting principles generally accepted in the United States (“GAAP”). Such measures, including underwriting profit (loss), adjusted net operating income, tangible equity, tangible common equity, adjusted net operating return on tangible equity (which is calculated as annualized adjusted net operating income divided by the average quarterly tangible equity balances in the respective period), and adjusted net operating return on tangible common equity excluding AOCI (which is calculated as annualized adjusted net operating income (loss) divided by the average quarterly tangible common equity balances in the respective period, excluding AOCI), are referred to as non-GAAP measures. These non-GAAP measures may be defined or calculated differently by other companies. These measures should not be viewed as a substitute for those measures determined in accordance with GAAP. Reconciliations of such measures to the most comparable GAAP figures are included at the end of this press release.

About James River Group Holdings, Ltd.

James River Group Holdings, Ltd. is a Bermuda-based insurance holding company that owns and operates a group of specialty insurance and reinsurance companies. The Company operates in three specialty property-casualty insurance and reinsurance segments: Excess and Surplus Lines, Specialty Admitted Insurance and Casualty Reinsurance. Each of the Company’s regulated insurance subsidiaries are rated “A-” (Excellent) by A.M. Best Company.

Visit James River Group Holdings, Ltd. on the web at www.jrvrgroup.com

For more information contact:

Brett Shirreffs
SVP, Finance, Investments and Investor Relations
[email protected]

 
James River Group Holdings, Ltd. and Subsidiaries

Condensed Consolidated Balance Sheet Data

(Unaudited)
 

($ in thousands, except for share data) 
March 31,
2023
  December 31,
2022
ASSETS      
Invested assets:      
Fixed maturity securities, available-for-sale, at fair value $ 1,898,758   $ 1,783,417
Equity securities, at fair value   116,091     118,627
Bank loan participations, at fair value   146,768     154,991
Short-term investments   25,061     107,812
Other invested assets   27,184     27,447
Total invested assets   2,213,862     2,192,294
       
Cash and cash equivalents   199,898     173,164
Restricted cash equivalents (a)   104,254     103,215
Accrued investment income   15,892     14,418
Premiums receivable and agents’ balances, net   326,499     340,525
Reinsurance recoverable on unpaid losses, net   1,541,497     1,520,113
Reinsurance recoverable on paid losses   158,761     114,242
Deferred policy acquisition costs   54,535     59,603
Goodwill and intangible assets   217,416     217,507
Other assets   372,473     401,994
Total assets $ 5,205,087   $ 5,137,075
       
LIABILITIES AND SHAREHOLDERS’ EQUITY      
Reserve for losses and loss adjustment expenses $ 2,841,993   $ 2,768,995
Unearned premiums   638,856     676,016
Funds held (a)   297,002     310,953
Deferred reinsurance gain   36,954     20,091
Senior debt   222,300     222,300
Junior subordinated debt   104,055     104,055
Accrued expenses   43,732     59,566
Other liabilities   284,382     276,435
Total liabilities   4,469,274     4,438,411
       
Series A redeemable preferred shares   144,898     144,898
Total shareholders’ equity   590,915     553,766
Total liabilities, Series A redeemable preferred shares, and shareholders’ equity $ 5,205,087   $ 5,137,075
       
Tangible equity (b) $ 555,351   $ 501,248
Tangible equity per share outstanding (b) $ 12.84   $ 11.63
Shareholders’ equity per share outstanding $ 15.71   $ 14.78
Common shares outstanding   37,619,226     37,470,237
       
(a) Restricted cash equivalents and the funds held liability includes funds posted by the Company to a trust account for the benefit of a third party administrator handling the claims on the Rasier commercial auto policies in run-off. Such funds held in trust secure the Company’s obligations to reimburse the administrator for claims payments, and are primarily sourced from the collateral posted to the Company by Rasier and its affiliates to support their obligations under the indemnity agreements and the loss portfolio transfer reinsurance agreement with the Company. The funds held liability also includes a notional funds withheld account balance related to the loss portfolio transfer retrocession transaction that our Casualty Reinsurance segment entered into in the first quarter of 2022, which is reduced quarterly by paid losses on the subject business.
(b) See “Reconciliation of Non-GAAP Measures”      

 
James River Group Holdings, Ltd. and Subsidiaries

Condensed Consolidated Income Statement Data

(Unaudited)
 
  Three Months Ended

March 31,

($ in thousands, except for share data)
2023   2022
REVENUES      
Gross written premiums $ 363,893     $ 359,936  
Net written premiums   183,220       175,859  
       
Net earned premiums   208,113       189,824  
Net investment income   25,772       16,267  
Net realized and unrealized gains (losses) on investments   407       (5,010 )
Other income   1,309       867  
Total revenues   235,601       201,948  
       
EXPENSES      
Losses and loss adjustment expenses (a)   155,288       135,608  
Other operating expenses   60,259       50,061  
Other expenses   603       368  
Interest expense   6,616       2,292  
Amortization of intangible assets   91       91  
Total expenses   222,857       188,420  
Income before taxes   12,744       13,528  
Income tax expense   3,136       3,323  
NET INCOME $ 9,608     $ 10,205  
Dividends on Series A preferred shares   (2,625 )     (875 )
NET INCOME AVAILABLE TO COMMON SHAREHOLDERS $ 6,983     $ 9,330  
ADJUSTED NET OPERATING INCOME
(b)
$ 21,591     $ 13,867  
       
INCOME PER COMMON SHARE      
Basic $ 0.19     $ 0.25  
Diluted $ 0.18     $ 0.25  
       
ADJUSTED NET OPERATING INCOME PER COMMON SHARE      
Basic $ 0.58     $ 0.37  
Diluted (c) $ 0.56     $ 0.37  
       
Weighted-average common shares outstanding:      
Basic   37,531,819       37,406,913  
Diluted   37,785,452       37,554,662  
Cash dividends declared per common share $ 0.05     $ 0.05  
       
Ratios:      
Loss ratio   66.5 %     71.4 %
Expense ratio (d)   28.4 %     26.0 %
Combined ratio   94.9 %     97.4 %
Accident year loss ratio   65.9 %     67.9 %
       
(a) Losses and loss adjustment expenses include a $16.9 million expense for unrecognized deferred retroactive reinsurance gain for the three months ended March 31, 2023.
(b) See “Reconciliation of Non-GAAP Measures”.
(c) The outstanding Series A preferred shares were dilutive for the three months ended March 31, 2023. Dividends on the Series A preferred shares were added back to the numerator in the calculation and 5,640,158 common shares from an assumed conversion of the Series A preferred shares were included in the denominator.
(d) Calculated with a numerator comprising other operating expenses less gross fee income (in specific instances when the Company is not retaining insurance risk) included in “Other income” in our Condensed Consolidated Income Statements of $1.1 million and $800,000 for the three months ended March 31, 2023 and 2022, respectively, and a denominator of net earned premiums.

 
James River Group Holdings, Ltd. and Subsidiaries

Segment Results
 
EXCESS AND SURPLUS LINES
 
  Three Months Ended

March 31,
   

($ in thousands)
2023   2022   %
Change
Gross written premiums $ 228,903     $ 204,282     12.1 %
Net written premiums $ 147,430     $ 125,710     17.3 %
           
Net earned premiums $ 151,359     $ 131,301     15.3 %
Losses and loss adjustment expenses excluding retroactive reinsurance   (99,189 )     (84,925 )   16.8 %
Underwriting expenses   (32,175 )     (24,919 )   29.1 %
Underwriting profit (a) $ 19,995     $ 21,457     (6.8 )%
           
Ratios:          
Loss ratio   65.5 %     64.7 %    
Expense ratio   21.3 %     19.0 %    
Combined ratio   86.8 %     83.7 %    
Accident year loss ratio   65.7 %     64.7 %    
           
(a) See “Reconciliation of Non-GAAP Measures”.

 
SPECIALTY ADMITTED INSURANCE
 
  Three Months Ended

March 31,
   

($ in thousands)
2023   2022   %
Change
Gross written premiums $ 124,551     $ 125,710     (0.9 )%
Net written premiums $ 26,725     $ 20,205     32.3 %
           
Net earned premiums $ 20,481     $ 19,318     6.0 %
Losses and loss adjustment expenses   (15,492 )     (15,435 )   0.4 %
Underwriting expenses   (5,458 )     (3,674 )   48.6 %
Underwriting (loss) profit (a), (b) $ (469 )   $ 209      
           
Ratios:          
Loss ratio   75.6 %     79.9 %    
Expense ratio   26.7 %     19.0 %    
Combined ratio   102.3 %     98.9 %    
Accident year loss ratio   76.5 %     79.6 %    
           
(a) See “Reconciliation of Non-GAAP Measures”.          
(b) Underwriting results for the three months ended March 31, 2023 and 2022 include gross fee income of $5.7 million and $5.6 million, respectively.

   
CASUALTY REINSURANCE  
   
  Three Months Ended

March 31,
     

($ in thousands)
2023   2022   %
Change
 
Gross written premiums $ 10,439     $ 29,944     (65.1 )%
Net written premiums $ 9,065     $ 29,944     (69.7 )%
             
Net earned premiums $ 36,273     $ 39,205     (7.5 )%
Losses and loss adjustment expenses excluding retroactive reinsurance   (23,744 )     (35,248 )   (32.6 )%
Underwriting expenses   (12,223 )     (12,794 )   (4.5 )%
Underwriting profit (loss) (a) $ 306     $ (8,837 )    
             
Ratios:            
Loss ratio   65.5 %     89.9 %      
Expense ratio   33.7 %     32.6 %      
Combined ratio   99.2 %     122.5 %      
Accident year loss ratio   60.3 %     72.6 %      
             
(a) See “Reconciliation of Non-GAAP Measures”.            
             


Underwriting Performance Ratios

The following table provides the underwriting performance ratios of the Company inclusive of the business subject to retroactive reinsurance accounting for loss portfolio transfers. There is no economic impact to the Company over the life of a loss portfolio transfer contract so long as any additional losses subject to the contract are within the limit of the loss portfolio transfer and the counterparty performs under the contract. Retroactive reinsurance accounting is not indicative of our current and ongoing operations. Management believes that providing loss ratios and combined ratios on business not subject to retroactive reinsurance accounting for loss portfolio transfers gives the users of our financial statements useful information in evaluating our current and ongoing operations.

  Three Months Ended

March 31,
  2023    2022 
Excess and Surplus Lines:      
Loss Ratio 65.5 %   64.7 %
Impact of retroactive reinsurance 7.7 %   %
Loss Ratio including impact of retroactive reinsurance 73.2 %   64.7 %
       
Combined Ratio 86.8 %   83.7 %
Impact of retroactive reinsurance 7.7 %   %
Combined Ratio including impact of retroactive reinsurance 94.5 %   83.7 %
       
Casualty Reinsurance:      
Loss Ratio 65.5 %   89.9 %
Impact of retroactive reinsurance 14.2 %   %
Loss Ratio including impact of retroactive reinsurance 79.7 %   89.9 %
       
Combined Ratio 99.2 %   122.5 %
Impact of retroactive reinsurance 14.2 %   %
Combined Ratio including impact of retroactive reinsurance 113.4 %   122.5 %
       
Consolidated:      
Loss Ratio 66.5 %   71.4 %
Impact of retroactive reinsurance 8.1 %   %
Loss Ratio including impact of retroactive reinsurance 74.6 %   71.4 %
       
Combined Ratio 94.9 %   97.4 %
Impact of retroactive reinsurance 8.1 %   %
Combined Ratio including impact of retroactive reinsurance 103.0 %   97.4 %
           

RECONCILIATION OF NON-GAAP MEASURES



Underwriting Profit

The following table reconciles the underwriting profit by individual operating segment and for the entire Company to consolidated income before taxes. We believe that the disclosure of underwriting profit by individual segment and of the Company as a whole is useful to investors, analysts, rating agencies and other users of our financial information in evaluating our performance because our objective is to consistently earn underwriting profits. We evaluate the performance of our segments and allocate resources based primarily on underwriting profit. We define underwriting profit as net earned premiums and gross fee income (in specific instances when the Company is not retaining insurance risk) less losses and loss adjustment expenses excluding the impact of loss portfolio transfers accounted for as retroactive reinsurance and other operating expenses. Other operating expenses include the underwriting, acquisition, and insurance expenses of the operating segments and, for consolidated underwriting profit, the expenses of the Corporate and Other segment. Our definition of underwriting profit may not be comparable to that of other companies.

  Three Months Ended

March 31,

($ in thousands)
2023   2022
Underwriting profit (loss) of the operating segments:      
Excess and Surplus Lines $ 19,995     $ 21,457  
Specialty Admitted Insurance   (469 )     209  
Casualty Reinsurance   306       (8,837 )
Total underwriting profit of operating segments   19,832       12,829  
Other operating expenses of the Corporate and Other segment   (9,282 )     (7,874 )
Underwriting profit (a)   10,550       4,955  
Losses and loss adjustment expenses – retroactive reinsurance   (16,863 )      
Net investment income   25,772       16,267  
Net realized and unrealized gains (losses) on investments   407       (5,010 )
Other expense   (415 )     (301 )
Interest expense   (6,616 )     (2,292 )
Amortization of intangible assets   (91 )     (91 )
Consolidated income before taxes $ 12,744     $ 13,528  
       
(a) Included in underwriting results for the three months ended March 31, 2023 and 2022 is gross fee income of $5.7 million and $5.6 million, respectively.
 



Adjusted Net Operating Income

We define adjusted net operating income as income available to common shareholders excluding a) the impact of loss portfolio transfers accounted for as retroactive reinsurance, b) net realized and unrealized gains (losses) on investments, c) certain non-operating expenses such as professional service fees related to a purported class action lawsuit, various strategic initiatives, and the filing of registration statements for the offering of securities, and d) severance costs associated with terminated employees. We use adjusted net operating income as an internal performance measure in the management of our operations because we believe it gives our management and other users of our financial information useful insight into our results of operations and our underlying business performance. Adjusted net operating income should not be viewed as a substitute for net income calculated in accordance with GAAP, and our definition of adjusted net operating income may not be comparable to that of other companies.

Our income available to common shareholders reconciles to our adjusted net operating income as follows:

  Three Months Ended March 31,
  2023   2022

($ in thousands)
Income

Before

Taxes
  Net

Income
  Income

Before

Taxes
  Net

Income
Income available to common shareholders $ 10,119     $ 6,983     $ 12,653   $ 9,330
Losses and loss adjustment expenses – retroactive reinsurance   16,863       14,406          
Net realized and unrealized investment (gains) losses   (407 )     (373 )     5,010     4,190
Other expenses   575       575       347     347
Adjusted net operating income $ 27,150     $ 21,591     $ 18,010   $ 13,867
                           



Tangible Equity (per Share) and Tangible Common Equity (per Share)

We define tangible equity as shareholders’ equity plus mezzanine Series A preferred shares and the unrecognized deferred retroactive reinsurance gain on loss portfolio transfers less goodwill and intangible assets (net of amortization). We define tangible common equity as tangible equity less mezzanine Series A preferred shares. Our definition of tangible equity and tangible common equity may not be comparable to that of other companies, and it should not be viewed as a substitute for shareholders’ equity calculated in accordance with GAAP. We use tangible equity and tangible common equity internally to evaluate the strength of our balance sheet and to compare returns relative to this measure. The following table reconciles shareholders’ equity to tangible equity and tangible common equity for March 31, 2023, December 31, 2022, and March 31, 2022.

  March 31, 2023   December 31, 2022   March 31, 2022

($ in thousands, except for share data)
Equity   Equity per
share
  Equity   Equity per
share
  Equity   Equity per
share
Shareholders’ equity $ 590,915   $ 15.71   $ 553,766   $ 14.78   $ 647,677   $ 17.30
Plus: Series A redeemable preferred shares   144,898         144,898         144,898    
Plus: Deferred reinsurance gain   36,954         20,091            
Less: Goodwill and intangible assets   217,416         217,507         217,779    
Tangible equity $ 555,351   $ 12.84   $ 501,248   $ 11.63   $ 574,796   $ 13.34
Less: Series A redeemable preferred shares   144,898         144,898         144,898    
Tangible common equity $ 410,453   $ 10.91   $ 356,350   $ 9.51   $ 429,898   $ 11.48
                       
Common shares outstanding   37,619,226         37,470,237         37,448,314    
Common shares from assumed conversion of Series A preferred shares   5,640,158         5,640,158         5,640,158    
Common shares outstanding after assumed conversion of Series A preferred shares   43,259,384         43,110,395         43,088,472    



Gulfport Energy Reports First Quarter 2023 Financial and Operational Results

Gulfport Energy Reports First Quarter 2023 Financial and Operational Results

OKLAHOMA CITY–(BUSINESS WIRE)–
Gulfport Energy Corporation (NYSE: GPOR) (“Gulfport” or the “Company”) today reported financial and operational results for the three months ended March 31, 2023 and provided an update on its 2023 development plan and financial position.

First Quarter 2023 and Recent Highlights

  • Delivered total net production of 1,057.4 MMcfe per day, above analyst consensus expectations

  • Reported $523.1 million of net income and $229.7 million of adjusted EBITDA(1), above analyst consensus expectations

  • Generated $304.1 million of net cash provided by operating activities and $63.1 million of adjusted free cash flow(1)
  • Reduced total debt outstanding by $145.0 million as compared to December 31, 2022 and had no borrowings under the revolving credit facility as of March 31, 2023

  • Completed spring borrowing base redetermination of revolving credit facility, which resulted in (1) borrowing base increase from $1.0 billion to $1.1 billion, (2) elected commitments increase from $700 million to $900 million, (3) addition of two financial institutions to the bank group and (4) extension of the maturity to May 2027

  • Repurchased 459.1 thousand shares for $32.9 million at a weighted average price of $71.61 per share during first quarter 2023

  • Repurchased 55.0 thousand shares of common stock for $4.4 million subsequent to the end of first quarter 2023; repurchased 3.4 million shares of common stock for $288.1 million(2) since the inception of the repurchase program

John Reinhart, President and CEO, commented, “We generated significant free cash flow during the first quarter despite the weaker commodity price environment, allowing us to continue to return capital to our shareholders while improving our already strong financial position as evidenced by our debt reduction of $145 million and the improvement of our leverage ratio. The current natural gas environment reinforces the importance of efficient and sustainable development of our assets and the focus of our team to enhance margins, optimize efficiencies, and protect the financial strength of the Company will further improve our strong positioning going forward. Our intention is to return substantially all of our adjusted free cash flow to our shareholders through common share repurchases after accounting for opportunistic acquisitions of accretive leasehold opportunities that high-grade our resource depth and provide optionality for our future development plans.”

Reinhart continued, “On the operational front, we are keenly focused on optimizing the development of our high-quality asset base in order to maximize the fundamental value of our company while protecting our balance sheet and prioritizing cash flow generation. In the first quarter of 2023, the Company delivered operational and financial performance better than analyst consensus estimates for both production and adjusted free cash flow while reducing cycle times and increasing capital efficiency. The team’s focus on efficiencies and continuous improvements in well productivity position us well as we enter the second quarter and continue to execute on our planned activity for the remainder of the year. In addition to our initial operational cadence improvements, we are also beginning to realize cost reductions in our capital program which reinforce our full-year guidance range for capital expenditures of $425 million to $475 million. We are focused on delivering additional savings in the current environment and will provide an update in future quarters. Our strong first quarter performance, both financially and operationally, positions the Company to deliver exceptional results while providing strategic optionality throughout the remainder of 2023.”

A company presentation to accompany the Gulfport earnings conference call can be accessed by clicking here.

1. A non-GAAP financial measure. Reconciliations of these non-GAAP measures and other disclosures are provided with the supplemental financial tables available on our website at www.gulfportenergy.com.

2. As of April 26, 2023.

2023 Guidance

The Company is reaffirming its 2023 guidance previously issued on February 28, 2023. Gulfport expects approximately 60% to 65% of its drilling and completion (“D&C”) capital expenditures for 2023 to occur in the first half of 2023 due to the higher level of development activity experienced early in the year. In addition, driven by strong production performance and efficiency gains achieved to date, the Company currently forecasts total net production to be trending to the high end of the previously provided guidance range of 1,000 MMcfe to 1,040 MMcfe per day.

Operational Update

The table below summarizes Gulfport’s operated drilling and completion activity for the first quarter of 2023:

 

 

Quarter Ended March 31, 2023

 

Gross

Net

Lateral Length

Spud

 

 

 

Utica

6

5.3

14,500

SCOOP

2

1.5

8,600

 

 

 

 

Drilled

 

 

 

Utica

7

6.6

13,500

SCOOP

1

0.7

8,700

 

 

 

 

Completed

 

 

 

Utica

5

4.8

15,800

SCOOP

 

 

 

 

Turned-to-Sales

 

 

 

Utica

SCOOP

 

Gulfport’s net daily production for the first quarter of 2023 averaged 1,057.4 MMcfe per day, primarily consisting of 738.5 MMcfe per day in the Utica and 318.9 MMcfe per day in the SCOOP. For the first quarter of 2023, Gulfport’s net daily production mix was comprised of approximately 89% natural gas, 8% natural gas liquids (“NGL”) and 3% oil and condensate.

 

 

Three Months Ended

March 31, 2023

 

Three Months Ended

March 31, 2022

Production

 

 

 

Natural gas (Mcf/day)

 

944,408

 

 

 

924,496

 

Oil and condensate (Bbl/day)

 

4,729

 

 

 

3,632

 

NGL (Bbl/day)

 

14,096

 

 

 

10,294

 

Total (Mcfe/day)

 

1,057,359

 

 

 

1,008,052

 

Average Prices

 

 

 

Natural Gas:

 

 

 

Average price without the impact of derivatives ($/Mcf)

$

3.32

 

 

$

4.87

 

Impact from settled derivatives ($/Mcf)

$

 

 

$

(1.34

)

Average price, including settled derivatives ($/Mcf)

$

3.32

 

 

$

3.53

 

Oil and condensate:

 

 

 

Average price without the impact of derivatives ($/Bbl)

$

72.16

 

 

$

92.51

 

Impact from settled derivatives ($/Bbl)

$

(1.04

)

 

$

(24.91

)

Average price, including settled derivatives ($/Bbl)

$

71.12

 

 

$

67.60

 

NGL:

 

 

 

Average price without the impact of derivatives ($/Bbl)

$

31.46

 

 

$

48.88

 

Impact from settled derivatives ($/Bbl)

$

0.77

 

 

$

(6.20

)

Average price, including settled derivatives ($/Bbl)

$

32.23

 

 

$

42.68

 

Total:

 

 

 

Average price without the impact of derivatives ($/Mcfe)

$

3.71

 

 

$

5.30

 

Impact from settled derivatives ($/Mcfe)

$

 

 

$

(1.38

)

Average price, including settled derivatives ($/Mcfe)

$

3.71

 

 

$

3.92

 

Selected operating metrics

 

 

 

Lease operating expenses ($/Mcfe)

$

0.21

 

 

$

0.19

 

Taxes other than income ($/Mcfe)

$

0.11

 

 

$

0.14

 

Transportation, gathering, processing and compression expense ($/Mcfe)

$

0.92

 

 

$

0.93

 

Recurring cash general and administrative expenses ($/Mcfe) (non-GAAP)

$

0.10

 

 

$

0.11

 

Interest expenses ($/Mcfe)

$

0.14

 

 

$

0.15

 

 

Capital Investment

Capital investment was $147.0 million (on an incurred basis) for the first quarter of 2023, of which $127.2 million related to drilling and completion (“D&C”) activity and $19.8 million related to leasehold and land investment.

Common Stock Repurchase Program

Gulfport’s board of directors previously authorized the Company to repurchase up to $400 million of its outstanding shares of common stock. Purchases under the repurchase program may be made from time to time in open market or privately negotiated transactions, and will be subject to available liquidity, market conditions, credit agreement restrictions, applicable legal requirements, contractual obligations and other factors. The repurchase program does not require the Company to acquire any specific number of shares. The Company intends to purchase shares under the repurchase program opportunistically with available funds while maintaining sufficient liquidity to fund its capital development program. The repurchase program may be suspended from time to time, modified, extended or discontinued by the board of directors at any time.

As of April 26, 2023, the Company had repurchased 3.4 million shares of common stock at a weighted-average share price of $84.38 since the program initiated in March 2022, totaling approximately $288.1 million in aggregate.

Spring Borrowing Base Redetermination

Gulfport recently completed its spring borrowing base redetermination and on May 1, 2023, the Company entered into the 3rd amendment to its credit agreement (the “Amendment”) governing the Company’s revolving credit facility. The Amendment, among other things, increased the borrowing base under the credit facility from $1 billion to $1.1 billion, with aggregate elected lender commitments increasing from $700 million to $900 million. The Company added two additional financial institutions to the bank group, bringing the total financial institutions participating in the Company’s revolving credit facility to 16. In addition, the Amendment extended the maturity of the credit facility by more than 18 months to May 1, 2027. The Amendment increases Gulfport’s financial flexibility to continue to execute its business plan and return capital to shareholders.

Michael Hodges, Gulfport’s CFO, commented, “We are pleased to announce the results of our successful spring borrowing base redetermination, which was driven by the underlying value of our high-quality resource base despite the current natural gas price environment. We greatly appreciate the support of our bank group as we position the Company to opportunistically deliver value to our stakeholders.”

Financial Position and Liquidity

As of March 31, 2023, Gulfport had approximately $3.5 million of cash and cash equivalents, no outstanding borrowings under its revolving credit facility, $74.4 million of letters of credit outstanding and $550 million of outstanding 2026 senior notes.

Gulfport’s liquidity at March 31, 2023, totaled approximately $629.1 million, comprised of the $3.5 million of cash and cash equivalents and approximately $625.6 million of available borrowing capacity under its revolving credit facility. Pro forma for the Amendment, Gulfport’s liquidity at March 31, 2023 increases by approximately $200 million.

Derivatives

Gulfport enters into commodity derivative contracts on a portion of its expected future production volumes to mitigate the Company’s exposure to commodity price fluctuations. For details, please refer to the “Derivatives” section provided with the supplemental financial tables available on our website at ir.gulfportenergy.com.

First Quarter 2023 Conference Call

Gulfport will host a teleconference and webcast to discuss its first quarter of 2023 results beginning at 9:00 a.m. ET (8:00 a.m. CT) on Wednesday, May 3, 2023.

The conference call can be heard live through a link on the Gulfport website, www.gulfportenergy.com. In addition, you may participate in the conference call by dialing 866-373-3408 domestically or 412-902-1039 internationally. A replay of the conference call will be available on the Gulfport website and a telephone audio replay will be available from May 4, 2023 to May 18, 2023, by calling 877-660-6853 domestically or 201-612-7415 internationally and then entering the replay passcode 13738078.

Financial Statements and Guidance Documents

First quarter of 2023 earnings results and supplemental information regarding quarterly data such as production volumes, pricing, financial statements and non-GAAP reconciliations are available on our website at ir.gulfportenergy.com.

Non-GAAP Disclosures

This news release includes non-GAAP financial measures. Such non-GAAP measures should be not considered as an alternative to GAAP measures. Reconciliations of these non-GAAP measures and other disclosures are provided with the supplemental financial tables available on our website at ir.gulfportenergy.com.

About Gulfport

Gulfport is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition and production of natural gas, crude oil and NGL in the United States with primary focus in the Appalachia and Anadarko basins. Our principal properties are located in eastern Ohio targeting the Utica formation and in central Oklahoma targeting the SCOOP Woodford and SCOOP Springer formations.

Forward Looking Statements

This press release includes “forward-looking statements” for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than statements of historical fact. They include statements regarding Gulfport’s current expectations, management’s outlook guidance or forecasts of future events, projected cash flow and liquidity, inflation, share repurchases, its ability to enhance cash flow and financial flexibility, future production and commodity mix, plans and objectives for future operations, the ability of our employees, portfolio strength and operational leadership to create long-term value, the rejection of certain midstream contracts and the assumptions on which such statements are based. Gulfport believes the expectations and forecasts reflected in the forward-looking statements are reasonable, Gulfport can give no assurance they will prove to have been correct. They can be affected by inaccurate or changed assumptions or by known or unknown risks and uncertainties. Important risks, assumptions and other important factors that could cause future results to differ materially from those expressed in the forward-looking statements are described under “Risk Factors” in Item 1A of Gulfport’s annual report on Form 10-K for the year ended December 31, 2022 and any updates to those factors set forth in Gulfport’s subsequent quarterly reports on Form 10-Q or current reports on Form 8-K (available at https://www.gulfportenergy.com/investors/sec-filings). Gulfport undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

Investors should note that Gulfport announces financial information in SEC filings, press releases and public conference calls. Gulfport may use the Investors section of its website (www.gulfportenergy.com) to communicate with investors. It is possible that the financial and other information posted there could be deemed to be material information. The information on Gulfport’s website is not part of this filing.

Investor Contact:

Jessica Antle – Director, Investor Relations

[email protected]

405-252-4550

KEYWORDS: Oklahoma United States North America

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo